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Abstract	
The	healthcare	sector	faces	vital	challenges,	on	the	one	hand	the	spread	of	chronic	
diseases	 at	 a	 global	 scale.	 On	 the	 other	 hand,	 rising	 delivery	 costs	 in	 healthcare	 create	 a	
necessity	for	innovation.	
Research	 show	 patients	 and	 caregivers	 as	 one	 of	 the	 sources	 for	 innovation	 in	
healthcare,	by	 self-providing	 treatments,	 therapies	or	medical	devices	 to	better	 cope	with	
their	 unmet	 needs,	 imposed	 by	 health	 disorders	 commercially	 unattractive	 for	 medical	
manufacturers’	investment	(Oliveira	et	al.,	2015).	
Van	der	Boor	et	al.	(2014)	concluded	that	high	levels	of	need,	the	existence	of	flexible	
platforms,	and	the	access	to	information	and	communication	technology,	contribute	to	the	
occurrence	of	this	phenomenon	in	the	developing	world.	
Our	 research	 questions	 are:	 What	 are	 the	 major	 drivers	 for	 user	 innovation	 in	
healthcare,	 in	 developing	 countries?	 Which	 socio-economic	 factors	 influence	 user	
innovations	 development	 in	 these	 countries?	 Which	 local	 complementary	 assets	 affect	
entrepreneurship?	 To	what	 extent	 can	user	 solutions,	 created	 in	 developing	 countries,	 be	
adopted	in	developed	regions?	
We	 applied	 a	 multiple	 case-study	 method,	 conducting	 eleven	 semi-structured	
interviews	and	four	surveys	of	“patient	innovators”	from	13	developing	countries.	
	 86.7%	 of	 the	 innovations	 were	 developed	 by	 users	 with	 a	 clear	 perception	 of	 the	
fragile	conditions	in	the	analysed	countries.	Reputation	achieved	amongst	their	communities	
was	 recognized	 by	 users	 as	 another	 major	 driver	 (46.7%).	 The	 most	 problematic	 socio-
economic	 factor	 verified	 is	 healthcare,	 where	 86.7%	 of	 user	 innovators	 reported	 issues.	
66.7%	 of	 users	 rely	 on	 complementary	 technologies	 as	 the	 major	 complementary	 asset.	
Furthermore,	20.0%	sample	solutions	could	be	adopted	by	developed	countries. 
 
 
 
 
 
 
 
 
 
 
Keywords: user innovation, healthcare, developing countries, complementary assets, socio-
economic factors, reverse innovation. 
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Resumo	
O	setor	da	saúde	enfrenta	desafios	vitais,	por	um	lado	devido	ao	alastramento	global	
de	doenças	crónicas.	Por	outro,	devido	aos	aumentos	nos	custos	da	saúde,	gerando-se	uma	
necessidade	de	inovação.		
Estudos	 mostram	 doentes	 e	 cuidadores	 como	 uma	 das	 fontes	 de	 inovação,	 ao	
criarem	 tratamentos,	 terapias	 ou	 dispositivos	 médicos	 para	 lidar	 melhor	 com	 as	
necessidades	 não	 atendidas,	 impostas	 por	 problemas	 de	 saúde	 comercialmente	 pouco	
atrativos	para	investimentos	dos	fabricantes	médicos	(Oliveira	et	al.,	2015).	
Van	 der	 Boor	 et	 al.	 (2014)	 concluiu	 que	 altos	 níveis	 de	 necessidade,	 existência	 de	
plataformas	flexíveis	e	acesso	a	tecnologias	da	informação	e	comunicação,	contribuem	para	
a	ocorrência	deste	fenómeno	no	mundo	subdesenvolvido.	
As	 questões	 de	 investigação	 são:	 Quais	 os	 principais	 fatores	 para	 a	 inovação	 de	
doentes	 utilizadores,	 nos	 países	 subdesenvolvidos?	 Que	 fatores	 socioeconómicos	 que	
influenciam	 o	 desenvolvimento	 de	 inovações	 por	 utilizadores	 nesses	 países?	 Que	 ativos	
complementares	 locais	que	afetam	o	empreendedorismo?	Em	que	medida	estas	 soluções,	
criadas	em	países	subdesenvolvidos,	poderão	ser	adotadas	em	regiões	desenvolvidas?	
Aplicamos	 um	 método	 de	 estudo-de-caso	 múltiplo,	 com	 quinze	 entrevistas	
semiestruturadas	 e	 quatro	questionários	 de	 “doentes	 inovadores”.	A	 amostra	 é	 composta	
por	13	países	subdesenvolvidos.	
86.7%	das	inovações	foram	desenvolvidas	por	utilizadores	conscientes	das	condições	
frágeis	 nos	 países	 analisados.	 A	 reputação	 que	 utilizadores	 inovadores	 adquirem	nas	 suas	
comunidades	é	outra	das	motivações	(46.7%).	A	saúde	é	o	fator	socioeconómico	verificado	
mais	 problemático,	 86.7%	 dos	 inovadores	 reportaram	 problemas.	 60.0%	 dos	 utilizadores	
apostam	 em	 marketing	 e/ou	 tecnologias	 complementares	 como	 ativos	 complementares.	
Além	disso,	20.0%	destas	inovações	podem	ser	adotadas	por	países	desenvolvidos. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-chave: inovação por utilizadores, saúde, países subdesenvolvidos, ativos 
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1. Introduction	
Patients constitute the largest group of stakeholders in the healthcare sector, furthermore 
Habicht, Oliveira and Shcherbatiuk (2012) noticed that the current services’ provision often 
fails to meet their needs. Several studies (Greco & Eisenberg, 1993; Shortell, Bennett & 
Byck, 1998; Shortell et al., 2001) concluded how difficult is to change the clinicians’ 
behaviors, the current medical practices, and the healthcare organizations, Faulkner & Kent 
(2001) added that, oftentimes, this happens due to regulations imposed by laws. Additionally, 
the rising costs on health and long-term care will continue to put pressure on public budgets 
over the next decades. In 2014, the percentage of Growth Domestic Product spent on public 
health along Organization for Economic Cooperation and Development (OECD) countries 
was, on average, 7.7%i of the total healthcare expenditure (12.4%ii). 
Innovation is seen as a critical way of improving the health systems’ ability to address the 
problems of aging populations and the rise of chronic diseases, while containing escalating 
costs (OECD, 2011b). Zaltman et al. (1973) consider innovation as a crucial component of 
productivity and competitive survival. As the changing global economy generates further 
fiscal and social pressures, additional reform approaches will be necessary (OECD, 
2011a). Herzlinger (2006), after an unsuccessful exploration on the reasons behind healthcare 
innovations, suggested a strategy that would make healthcare better and cheaper. This strategy 
consists of “breaking down” the problems by look at the different types of innovations and 
forces affecting them, like policy makers, or consumers.  
Von Hippel (2005) explored consumers as a source of innovation by making use of 
Adam Smith’s statement in 1776, “a great part of the machines made use of in those 
manufacturers in which labor is most subdivided, were originally the invention of common 
workmen (…)”. These workmen are defined by von Hippel (1976) as user innovators, the 
ones that “invented, prototyped and field-tested instruments”. 
We find this phenomenon’s presence across different industries (Enos, 1962; Freeman, 
1968; Riggs & von Hippel, 1996; Tietz et al., 2004; Lüthje, Herstatt, & von Hippel, 2005; 
Baldwin, Hienerth, & von Hippel, 2006; Oliveira & von Hippel, 2011), either in product 
novelties (consumer or industrial), or services. User innovators begin by developing solutions 
for personal use, without considering the value of them for others (Zejnilović, Oliveira, & 
Canhão, 2016). 
One particular field where user innovation has given signs of its existence and 
importance is healthcare (Habicht et al., 2012; Oliveira & Canhão, 2014; Oliveira et al., 2015; 
                                                i	http://bit.ly/2rOv3RN	ii	http://bit.ly/2rLDVrY	
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Zejnilović et al., 2016; von Hippel, 2016). Patients and caregivers are the ones who know best 
their difficulties and challenges caused by health conditions (Habicht et al., 2012). Through a 
sample with 500 rare diseases patients and caregivers, Oliveira et al. (2015) observed that 8% 
were considered as introducers of new solutions to the world. 
When looking at the geographic origin of innovations, researchers have also explored the 
role of users as innovators in developing countries. Van der Boor, Oliveira and Veloso (2014) 
verified, through a study on mobile banking services, that as users in developing markets 
increasingly have access to many of the same technologies, the opportunity for possible 
innovations expands on the user’s side. The same authors (2014) even observed that three-
quarters of the innovations, originated from developing countries, have already diffused to 
developed ones. As an example, the case of Gatorade® (Govindarajan & Trimble, 2012) 
prove that solutions created on the developing side can have an impact on the developed 
world. This liquid’s recipe was created in Bangladesh to be used in cholera victims for rapid 
rehydration, and later on adopted by the Western world as an energy drink. 
Considering need as a determinant driver for innovation and developing countries as 
high-need environments, this study aims to examine the extent to which patients and 
caregivers (users) innovate in these regions, the socio-economic factors that influence these 
innovations, and the assets these innovators acquire in order to diffuse.  
It is of major importance to understand the concept of reverse innovation, how it occurs, 
and its impact. With this in mind, our research proposes to answer the following questions: 
Ø Research	Question	1:	What	are	the	major	drivers	for	user	innovation	in	healthcare,	in	emerging	countries?	
Ø Research	Question	2:	Which	 socio-economic	 factors	 influence	 user	 innovations	 in	these	countries?	
Ø Research	Question	3:	Which	local	complementary	assets	affect	entrepreneurship?	
Ø Research	 Question	 4:	 To	 what	 extent	 can	 user	 solutions,	 created	 in	 developing	countries,	be	adopted	by	developed	regions?	
The structure of this dissertation is the following: the coming section comprises a review 
on the existent literature, which served as basis for our research. Then, we present the 
methodology used, including the coding used to evaluate user driven solutions. Chapter four 
brings the major findings, supported by evidence obtained from the sample. Lastly, we will 
retrieve the major outcomes, present limitations confronted during the study, and suggest 
recommendations for further research. 
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2. Literature	Review	
This section aims to inspect the current available literature that explains and supports the 
patient innovation phenomenon. This enables to analyse the existent theory at our disposal, to 
verify the academic application on this matter and provide cases of novel solutions developed 
by users. 
First, we present an overview on the current state of the socio-economic conditions 
within the healthcare system, particularly addressing developing countries, and exposing the 
major problems amongst these regions. Subsequently, we scrutinize what to expect for this 
sector. 
Afterwards, we introduce the user innovation concept, by giving a notion of its 
importance and providing evidence of its existence throughout numerous fields. Moreover, 
we provide literature on the user innovation process stages and the user entrepreneurial 
concept. Regarding the presence of this phenomenon in the healthcare system, we presented 
literature allowing to understanding why patients, caregivers and collaborators innovate and 
why this is becoming important for the academic society. Ultimately, we introduced literature 
on user innovation across developing countries, helping us to understand the users’ major 
motivations, and adopted processes, to innovate. Within this, we examined and explored the 
reverse innovation phenomenon. 
2.1. Healthcare	System	
Notwithstanding, the exponential advancements in technology that are transforming 
healthcare (Taylor, 2015), this sector is still consuming an escalating share of income in 
developed and developing nations alike. In a world where public health expenditure in OECD 
countries represents 6.7% from the 9.3% of total health expenditure (OECD, 2011a), major 
findings can help to the cost savings policy that can be followed. 
There are both demographic and non-demographic reasons for these rising costs. Whilst, 
the demographic ones relate broadly to the age structure of the population and the evolution 
of its health status, the critical non-demographic driver is income (OECD, 2013). In this 
mode, OECD average health expenditure to GDP ratio is projected to more than double 
between 2010 and 2060, whereas regarding BRICS is set to more than triple (OECD, 2013). 
On average, across OECD countries, about 20% of health spending is paid directly by 
patients, which can create barriers to healthcare access (OECD, 2015a). As an illustration, and 
considering the low-income households, OECD (2015a) reported that are four to six times 
more likely to present unmet needs for medical and dental care due to financial or other 
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reasons, than those with higher income. 
The current healthcare system rewards innovation that prolongs life (Habicht et al., 
2012). Indeed, advances in this sector have been made, still, in many countries there is room 
to implement best practices in acute care, further reducing mortality (OECD, 2015b). 
However, improvements should be done carefully and technology can be overused, if offered 
to patients for whom innovations provide no benefit (Bodenheimer, 2005). 
OECD (2011a) advises that a structural pressure is the long-term fundamental shift of 
wealth creation, away from developed nations towards emerging economies, meaning that the 
most developed nations should attribute more funds to less developed nations. 
2.1.1. Healthcare	in	Developing	Countries	
Many people along the developing world still live without access to healthcare, from 
which they could benefit greatly (O'Donnell, 2007). Akin et al. (1987) observed that, in 1983, 
low- and middle-income countries experienced, on average, infant mortality rates about eight 
times higher than the industrialized countries. Furthermore, there are large discrepancies 
between rich and poor in these underprivileged countries with respect to health and education 
outcomes (Devarajan & Reinikka, 2004). In addition, O’Donnell (2007) stated that effective 
healthcare interventions are underutilized across developing nations. 
Additionally, incentives for effective healthcare delivery are scarce and, as the nature of 
health problems change, the effect on the population’s overall health condition will be 
difficult to verify (Jack, 1999). As an example, Devarajan and Reinikka (2004) conducted a 
survey on primary healthcare facilities in Bangladesh and found a doctors’ absenteeism rate 
of 74%. 
Besides the efforts that are being made, such as health financing, price subsidies, and 
poverty alleviation programs, O’Donnell (2007) stressed that the difficulty lies on detailed 
policy initiatives’ design, aiming to tackle root problems within severe economic, 
institutional, and political constraints. The vested interests that block the poor’s access to 
better services will not be overcame, along with a limited capacity that unable the adoption of 
these radical changes (Devarajan & Reinikka, 2004). 
Indeed, Ranck (2011) discovered that the communication gap between managers of 
health services, health workers at the periphery and the patient population they serve, has 
been a barrier to an efficient service delivery. Meanwhile, the widespread use of SMS, the 
least-expensive mobile phone function, offers a solution that could rapidly overcome 
communication weaknesses, potentially leading to improved delivery of health services and 
better health outcomes (Zurovac, Talisuna, & Snow, 2012). Conclusions from the study 
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promoted by Déglise, Suggs and Odermatt (2012) showed that text messaging seems to 
improve the process of care and was well accepted by both health workers and the targeted 
population. The majority of users and beneficiaries were familiar with mobile phones and 
SMS for private and professional use, and technology was reliable. 
Some modern health innovations, especially technological advancements, have been 
inaccessible to developing countries for much of the 20th century because of both financial 
constraints and general lack of infrastructures. Harvey et al. (2014) noticed the change over 
the past decade, major healthcare companies started to look to the developing world in order 
to compensate slow growth in more developed nations. Consider the portable ultrasound 
machines’ example, they were originally produced to meet urgent diagnostic needs in 
resource-limited war zones, but manufacturers soon recognized their potential to diagnose 
gaps in resource-limited settings within the developing world. Albeit small-cap ultrasound 
manufacturers were the first to explore this market, more recently, large-cap imaging 
equipment manufacturers entered this market, by offering their own portable low-cost 
ultrasound models (Harvey et al., 2014).  
Notwithstanding, the alert given by O’Donnell (2007) for the urgent need to establish 
mechanisms that would increase the availability and improve the quality of healthcare in the 
developing world, there are many innovations in regulation of care holding promising to 
improve access for the most needed (Peters, 2008). 
These regions have the potential to greatly improve health service efficiency, expand or 
scale up treatment delivery to thousands of patients in developing countries, and improve 
patient outcomes (Blaya, Fraser, & Holt, 2010). 
For O’Donnell (2007), lowering the barrier of distance is of crucial need, although it 
requires either taking people to services or services to people. 
2.1.2. Healthcare	Perspectives	
Innovation is seen as an important path to follow in order to increase the system’s 
efficiency, thus lowering the costs (Robinson & Smith, 2008). 
Akin et al. (1987) summarized the three main problems in the healthcare sector: firstly, 
the insufficient spending on cost-effective health programs, which translates into an allocation 
problem; secondly, poor quality public healthcare programs, reflecting inefficiency; last but 
not less important, an inequitable distribution of health services’ benefits. 
By making a comparison with the field of consumer goods, von Hippel (2016) described 
the possibility of complementing the traditional, expert-driven model of public health 
intervention development with a health intervention model that builds upon solutions 
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developed by the public. The same author (2016) stated this could be one of the ways to 
improve efficiency in a field desperate for a cost saving model. 
Despite the lack of infrastructure and backup systems in resource-poor environments, 
well-designed e-health solutions may have a much larger impact on the quality of care than in 
more developed areas (Blaya et al., 2010). Thus, any new opportunity that may improve 
individual well-being and address to the cost issue is warmly welcomed by healthcare 
stakeholders (Zejnilović et al., 2016). 
Examples like reliable home tests for pregnancy and HIV, administered by patients, or 
laparoscopic instruments that empty the hospital’s operating rooms in favour of ambulatory 
facilities (Robinson & Smith, 2008), are two innovative examples within this field. 
2.2. User	Innovation	
Amabile (1997), broadly described innovation as something novel and useful, earlier 
Porter (1990) stated that innovation include either new technologies or new ways of doing 
things. Hence, it is something new that breaks into the market or society, and defined as 
something original and more effective (Frankelius, 2009). 
According to Bogers, Afuah and Bastian (2010), the user innovation concept started to be 
developed in the 1970s. Von Hippel (1976) acknowledges these users as the ones that 
“invented, prototyped and field-tested instruments”, other than manufacturers. The same 
author (2005) distinguishes users from manufacturers, being the first “firms or individual 
consumers that expect to benefit from using a product or a service”, contrasting with 
manufacturers that “expect to benefit from selling a product or a service”. 
Users exploiting products as inputs in their innovation processes, or using products to 
satisfy their personal needs, are considered user innovators (Bogers et al., 2010). This type of 
users, at a first stance, must have a strong unfulfilled need (Urban & von Hippel, 1988), not 
likely to be solved by others (Morrison, Roberts, & von Hippel, 2000), and they need to 
possess “local” and valuable information for the innovation (Lüthje et al., 2005). 
Von Hippel (1986, 2005), and Urban and von Hippel (1988) go further and defined lead 
users, as the ones who find future general needs, as the marketplace face the same needs 
months or years after them. Lead users can provide both new product concept and design data 
to the market (von Hippel, 1986). Lüthje (2004) classified lead users as the ones that provide 
sources of new service ideas with high commercial potential. In addition, Oliveira and von 
Hippel (2011) classified a service innovation as user-developed if the developer expects to 
“benefit from use”, and provider-developed if it expects to “benefit from sales”. 
Altogether, Enos (1962) reported that nearly all the most important innovations in oil 
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refining were developed by user firms; Freeman (1968) found that the most widely licensed 
chemical production processes were improved by final users; von Hippel (1976, 1988) 
noticed that users were the actual developers of 82% of all commercialized scientific 
instruments and 63% of all semiconductor and electronic subassembly manufacturing 
equipment innovations; Pavitt (1984) discovered that a considerable number of inventions by 
British firms were for in-house use; Shah (2000) identified that the most commercially 
important equipment innovations in four sporting fields have been developed by individual 
users. 
It is becoming increasingly easier for many users to get what they want by designing it 
for themselves (von Hippel, 2005). Users are getting more access to tools and technologies, 
like cell phones and Internet, allowing them to solve problems in novel ways (Baker & 
Nelson, 2005), the costs for users to overcome a variety of unmet needs are greatly reduced 
(Van der Boor et al., 2014). 
Von Hippel (2005) defends that products, services, and processes developed by users 
become more valuable to society if diffused to others who can also benefit from them. 
Oftentimes, innovators freely reveal their solutions because it is the best or the only practical 
option available to them, and provide innovators with significant private benefits (von Hippel, 
2005). Raymond (1999) found that users who freely reveal what they have done often find 
that others improve or suggest improvements to the innovation, for mutual benefit, just then 
they diffuse either within peer-to-peer networks, or through a producer that offers the 
innovation in a market (Harhoff, Henkel, & von Hippel, 2003; Baldwin et al., 2006; De Jong 
et al., 2015). 
The available literature on user innovation (Enos, 1962; Freeman, 1968; Pavitt, 1984; von 
Hippel, 1988; Shah, 2000) has proven this phenomenon exists across different fields. Take the 
following studies as examples: after studying the role of users in software development, Voss 
(1985) discovered the circumstances in which users lead the development of new 
applications; Riggs and von Hippel (1996) examined an early form of electronic home 
banking that utilized a telephone channel between customer and bank, relating it with the user 
development of novel banking services; Oliveira and von Hippel (2011), based on a sample of 
all important retail and commercial service innovations commercialized by banks between 
1975 and 2010, built the first study on the role of user innovators in the development of new 
financial services. 
A more recent phenomenon was reported by von Hippel (2016). Free innovation consists 
of innovations developed and given away by consumers as a “free good”, resulting in social 
welfare improvements. As the author defends (2016), free innovation is not money-driven, 
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and incorporates two criteria: on one hand, has to be developed by consumers at private cost 
and during leisure time. On the other hand, can be potentially acquirable by anyone without 
payment. All in all, free innovators benefit from such innovations through the fun and 
learning from developing them. 
2.2.1. Drivers	in	User	Innovation	
Considerable research (Franke, von Hippel, & Schreier, 2006; Urban & von Hippel, 
1988) showed that individual need is often a more important driver for innovation by users, 
than potential market size. Following this, users may innovate if they are able and willing to 
pay for the development of something that is not available on the market (von Hippel, 2005). 
Oftentimes customer needs in a given market are heterogeneous, in addition standard products 
available in the marketplace repeatedly leave important needs unfulfilled (Franke & von 
Hippel, 2003). 
As noted, transfer information from the users’ side to manufacturers can be costly and it 
might not be accurate, known as “sticky” information (von Hippel, 1994). Von Hippel (1998) 
and Kuusisto et al. (2013) concluded it is more appropriate for users to solve their own needs 
instead of depending on “manufacturer-based” solutions. 
“Local solution information” is another driver for user driven innovations, verified 
through a study on innovations from mountain bikers by Lüthje et al. (2005). Stickiness of 
either need or solution knowledge diminishes the opportunity to find a solution for a given 
problem (Kuusisto et al., 2013). 
In their studies, Lerner and Tirole (2002), and Lakhani and von Hippel (2003), consider 
“local technical knowledge” as a driver for the creation of user innovations. The acquired 
enjoyment as users perform an innovation activity, whether by fun or to increase the required 
knowledge associated to the solution, constitute an incentive for users to came up with 
solutions (Lakhani and von Hippel, 2003). Moreover, the reputation derived from making 
high-quality contributions to the community is also perceived as a driver to develop user 
solutions (Rheingold, 1993; Constant, Sproull, & Kiesler, 1996; Raymond, 1999; Lerner & 
Tirole, 2002; Lakhani & von Hippel, 2003). Through a study on user innovations across the 
consumer goods industry, Lüthje (2004) noticed the level of experience and expertise with a 
solution’s technicality increases the likelihood to innovate. 
2.2.2. The	process	behind	User	Innovation	
As Røtnes and Dybvik Staalesen (2009) concluded, from a study on Nordic countries, the 
innovation process can vary from user to user, and it goes through distinctive innovation 
stages. 
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Every process starts with a need and an identification of the problem that users face 
(Kuusisto et. al, 2013). Afterwards, the innovation process starts, comprising four stages: 
ideation, specification, implementation, and diffusion (Kuusisto et. al, 2013; Lüthje, 2004; 
Lüthje et al., 2005; Baldwin et al., 2006; von Hippel, 2005; Shah, 2000). 
The ideation phase is characterized by the moment where users idealize a product, 
service, or strategy, enabling to overcome the problem, formerly identified as such. Users 
have the idea on their minds but do not “drawn it up” (Lüthje, 2004). 
Moving to the following stage indicates there was a planification of the idea, such as a 
draw, or a model, indicating that the user has followed up the first step and is able to describe 
the solution and how to develop it (Oliveira, 2014). This is called specification and implies 
there is not yet a final product, however might have been already some experimentation. 
 Subsequently, we have the development of the solution, in which user innovators 
materialize what has been idealized in the previous stages and is ready to be used, whether as 
a basic or an advanced structure. Von Hippel (2005) states the solution can be something 
existent, used with other purpose, an incremental adaptation/innovation, something novel, or 
an existing solution adopting a low-cost approach. This step regards just to a personal use, 
meaning that no diffusion of the solution has been made (Oliveira, 2014). 
Finally, and after the user experienced personally the solution, it makes an effort to 
communicate the novelty to others. 
2.2.3. User	entrepreneurs	
Usually, after becoming innovators, users decide between selling their ideas to 
established manufacturers, create a venture with them, or settle a company and start selling 
their own products or services (von Hippel, 2005). This latest option is known as user 
entrepreneurship and, as von Hippel (2005) stated, after obtaining a benefit from using a 
developed product or service, users can opt for the commercialization of their solutions, 
profiting from them. This type of entrepreneurs contrast with the remaining as the latter are 
only focused on financial benefits derived from solutions developed (Shcherbatiuk & 
Oliveira, 2012). 
After analysing the behaviour of user innovators in three countries, von Hippel, Ogawa 
and de Jong (2011) concluded that users who develop innovations do not need a superior 
effort to become “casual entrepreneurs”. As these same authors (2011) defend, user driven 
innovations are becoming common and easier, thus they do not need to give up from their 
careers. 
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It has been studied (Shah & Tripsas, 2007; Amit, Muller & Cockburn, 1995) there is a 
higher probability to have users entering in industries that offer higher levels of enjoyment 
(regardless the economic benefit, like the case of producers) and lower opportunity costs. 
We can find available literature on this topic across distinct industries: in the 
microcomputer and stereo components (Langlois & Robertson, 1992), within radical sports 
(Shah, 2000), or along the mountain bicycle business (Lüthje et al., 2005). 
2.2.4. User	Innovation	in	Healthcare	
Goeldner & Herstatt (2016) distinguish professional users (physicians and nurses) from 
non-professional users (patients and relatives). Bearing this in mind, Habicht et al. (2012) 
characterize patient innovators as those who come up with novel treatments, strategies, and 
medical or non-medical equipment to help them better cope with their diseases. Within this 
field, user innovators face particular needs, which serve as drivers for the creation and 
development of solutions (Habicht et al., 2012), these drivers will be extensively covered 
along the methodology section. 
Rare diseases’ patients tend to be underserved both clinically and scientifically (Griggs et 
al., 2009). Aiming to find possible solutions for this problem, Oliveira and Canhão (2014) 
stressed that, oftentimes users “can serve themselves”. Thus, users might be recognized as 
innovators in regards to services they deliver to themselves. 
An enquiry (von Hippel et al., 2014; De Jong et al., 2015) estimates that 4 to 6% of US, 
Japan, Finland, and the UK citizens modify or create new products and services for personal 
use, and up to 7% of these innovations are classified as healthcare products. Furthermore, 
from a study with 500 rare diseases’ respondents, Oliveira et al. (2015) portray that 36% of 
the respondents claim they have innovated, which after validation from two medical experts, 
8% were considered to introduce something new to the world. These authors (2015) also 
reported a positive relationship between the impact of a solution on the respondents’ overall 
quality of life, and likelihood of solution sharing. In addition, Oliveira and Canhão (2014) 
noted an inverted U relationship between age and solution sharing. 
Although qualitative research (Frydman, 2009) found that patients and caregivers are the 
drivers of institutional research, Oliveira et al. (2015) concluded they have also invented 
countless valuable solutions in order to improve their own personal health conditions. 
Oliveira and Canhão (2014) described the case of Tal Golesworthy, a process engineer who, 
in 1992, was diagnosed with Marfan Syndrome, a rare disease resulting in a decreasing 
functionality and resilience of the aorta. He reached to a point when surgery was inevitable, 
forcing him to a lifetime anticoagulation therapy. As an engineer and with technical 
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knowledge, he decided to create a more suitable solution for himself, and invented the 
External Aortic Root Support (EARS), matching the patient’s aorta and eliminating the need 
for anticoagulant drugs. 
Many evidences of innovations by patients made a strong impact on disease related 
practices, some representing state-of-the-art technology (Habicht et al., 2012; Oliveira et al., 
2015). However, research (Habicht et al., 2012; Oliveira & Canhão, 2014; Oliveira et al., 
2015) defends this matter is not sufficiently explored, yet. 
2.2.5. User	Innovation	in	Developing	Countries	
Need is crucial towards innovation, in two ways: on one hand, high levels of need 
increase the number of user innovators (Urban & von Hippel, 1988; Franke et al., 2006). On 
the other hand, high need increases diffusion rates due to the growing potential market size 
(Mansfield, 1968; Geroski, 2000). Unique market needs and scarcity of alternatives can lead 
to valuable innovations from developing regions (Van der Boor et al., 2014). 
To the best of our knowledge, just a few studies (e.g. Govindarajan & Trimble, 2012; 
DePasse & Lee, 2013; Van der Boor et al., 2014; Snowdon et al., 2015) have been done up to 
now, to understand this phenomenon in developing regions. 
Van der Boor et al. (2014), from their study on mobile banking services, concluded that 
85% of the innovations within this field were originated from emerging markets. By 
perceiving that innovations occur more often in places where need is high, corroborates the 
finding that the majority of innovations are stimulated by market needs, rather than 
technological opportunity (Utterback, 1974; Hipp, & Grupp, 2005). 
If we take the study from Acemoglu and Linn’s (2004) as example, we conclude that a 
larger potential market size for a new drug, leads pharmaceutical firms to invest more in its 
development. This perspective shows that investment decisions are skewed towards the most 
developed and rich markets, instead of addressing people and issues with higher needs (Van 
der Boor et al., 2014). 
Studies performed previously (Schmookler, 1966; Mansfield, 1968; Mowery & 
Rosenberg, 1979), verify a positive relation between expected benefit from innovation and 
investment to innovate. After a study on the pharmaceutical industry, Trouiller et al. (2002) 
considered that, not only the levels of investment are lower in markets with a lower potential 
for profits, but the quantity of commercialized drugs for malaria is also smaller. With this 
description in hand, it is more likely to find a wider range of unmet needs, as well as 
customers who potentially create solutions to meet their own needs (Van der Boor et al., 
2014). As is the case of developing markets, where the portfolio of commercially offered 
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products and services is typically smaller and of lower quality (Flam & Helpman, 1987; 
Trouiller et al., 2002). 
By having as starting point the previously mentioned drugs for malaria’s case, Van der 
Boor et al. (2014) listed the main contributors to innovations in these countries as the high 
level of need, the existence of flexible platforms and an increasing access to ICT. 
Considering the case studied by Sternin and Choo (1999) on Vietnamese childhood 
malnutrition, where the innovators were the mothers of malnourished children and the 
consequences of their poor food regime triggered the need to innovate. Aiming to tackle their 
kids’ problem, they changed the children’s food habits and improved their quality of life. 
After these results, the approach to deal with the problem was diffused into other regions like 
Bangladesh, Bhutan, Egypt, Mali, Mozambique and Nepal. In line with this, Van der Boor et 
al. (2014), found that services developed by users diffused at more than double the rate of 
producer-innovations. 
2.2.5.1. Reverse	Innovation	
Several studies (Flam & Helpman, 1987; Grossman & Helpman, 1991) found evidence of 
a conversion in quality regarding North and South, across some industries. This reality, along 
with a lag reduction between industries in both regions, presents a higher possibility that 
products and services created in the South will also be new to the world (Van der Boor et al., 
2014), known as reverse innovation. 
Literature (Immelt, Govindarajan & Trimble, 2009; Govindarajan & Trimble, 2012) 
defines reverse innovation as a process firstly adopted in developing regions and then in the 
developed world. 
Altogether, Van der Boor et al. (2014), observed that three-quarters of the innovations 
originated from emerging markets have been diffused to OECD countries. Consider the 
Ushahidi’s case (DePasse & Lee, 2013), a crowdsourcing program used to map disaster 
impact and response (firstly used during the 2008 Kenyan presidential election and 
subsequently applied in 2010’s Haitian earthquake’s aftermath). After the success in these 
low-income countries settings, “crossed over” to USA (high-income country), aiming to 
monitor infrastructure damage during hurricanes. 
Reverse innovation can be successful due to the unique characteristics of developing 
countries that provide powerful incentives, or “gaps”, leading to innovation (DePasse et al., 
2016). 
In order to sum up this phenomenon, DePasse and Lee (2013) designed a model to be 
applied in the healthcare field, presented in Figure 1 (DePasse & Lee, 2013). Composed by 
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four steps, these authors (2013) describe them. Being the first an identification of the 
problem, a high-priority complication common to both low income countries and high income 
countries, and subject to more favourable innovation conditions in the lower-income setting. 
The second one consists of LIC innovators that develop and test new ideas, and then share 
these solutions with LIC early adopters. Thirdly, there is “cross-pollination” from lower- to 
higher-income settings. Lastly, HIC early adopters will be more likely to embrace it. 
 
Figure	1	-	A	model	for	reverse	innovation	in	health	care	
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3. Research	context	and	methods	
This study was conducted through a multiple case-study method, defined by Yin (1984, 
2009) as an “empirical inquiry that investigates a contemporary phenomenon within its real-
life context”.  The same author (1984,  2009) recommends this approach  when there is  no 
clarity on the boundaries between phenomenon and context, and when a variety of evidence 
sources have been used. 
Figure 2 outlines the methodology applied along the curent research. 
 
Figure	2	-	Methodology	used	
3.1. Approach	
Research (Yin,  1984;  Eisenhardt,  1989;  Leonard-Barton,  1990) shows the case study 
method is the most accurate when addressing to complex phenomena, which are not carefuly 
studied  or entirely  understood. Taking into account that  our research enquiry consists  of 
“how” and “why” type  of  questions,  Yin (1984) considers this  method as the  one to  be 
applied. Al in al, the presence of user innovations in healthcare, particularly in developing 
countries is, to the  best  of  our  knowledge, largely unexplored  by  user innovation theory in 
general. Hence, we chose this method in order to validate the curent literature on this mater, 
or to start considering new theory that might be supported through empirical research. 
This particular approach can be exploratory, explanatory, or even descriptive (Yin, 1984). 
The structure chosen was an exploratory one, which refers to a research handled for a problem 
that has not been studied clearly (Shields & Rangarjan, 2013). 
The case study  method can acquire either the form  of single  or multiple case  designs 
(Yin, 1984), being the later prefered by having a greater capacity to be externaly validated 
(Dul & Hak, 2007). 
3.2. Country	Selection	
The list of countries under analysis was chosen taking into account the diferent levels of 
development  worldwide, and  whether they  were accurate representatives of the  developing 
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countries’ characteristics socio-economic characteristics. Thus, we opted for using the country 
classification lists by the World Bank and the UN, referent to 2016. We chose not to focus 
just on the economic criteria but to address other conditions as well. Consequently, we 
followed the UN Development Programme’s Country Classification System, built from the 
Human Development Index to capture the multifaceted nature of development (Nielsen, 
2011). 
Sullivan and Sheffrin (2003) considered a developing economy, or less developed 
country, as a nation with a relatively less developed industrial base and a lower HDI. 
Considering this, we decided to analyse one economic criteria and nine social indicators. A 
definition of each is provided on Exhibit 16. 
With these measures, we have reached to a final list of 54 countries across Africa, Asia 
and South America (Exhibit 17). 
3.3. 	Innovations	Selection	
We encompassed the grounded theory to collect data. Amongst all the discovered 
innovations, only the ones created to solve a personal need, a need of a relative or close 
friend, or by persons facing a general need in their community, were considered. We coded 
them as patients, caregivers, or collaborators, respectively, having as base the definitions 
provided by von Hippel (2005, 2016) and Habicht et al. (2012). Although this led to a reduced 
number of innovations validated, it led to more reliable findings, considering the theory on 
user innovation. 
Our search was mainly online, through search engines like Google and DuckDuckGo, 
using combinations of keywords such as “came up with”, “create to help”, or “developed”. 
Besides, worldwide newspapers, blogs and articles have also been consulted. 
The expertise of the Patient Innovationiii team provided us a sound knowledge on how to 
find solutions, and how to identify and describe the user innovation phenomenon in 
healthcare. Additionally, from the pool of more than 700 solutions, we have selected three 
user innovations previously identified as such. 
Overall, the final sample includes 36 solutions, by 38 users (since 2 of them were co-
authored), from 21 developing countries (Exhibit 18). 
3.4. Data	Collection	and	Sample	
Afterwards, we have decided to gather information through interviews, by virtue of what 
Eisenhardt and Graebner (2007) stated, “interviews are a highly efficient way to gather rich, 
                                                iii	An	online	and	free-access	repository	of	open	knowledge	containing	healthcare	solutions	(www.patient-innovation.com)	
	 	 23	
empirical data, especially when the phenomenon of interest is highly episodic and 
infrequent”. In some cases, innovators were not available for an interview, so they agreed to 
answer a survey.  
The available data source is a result of eleven semi-structured and extensive interviews 
and four surveys. All the innovators were contacted by e-mail and social networks, and the 
interviews were conducted via Skype and Whatsapp. The interviews followed a script 
(Exhibit 21), and they were recorded and conducted by a unique interviewer (the author), in 
order to keep consistency along the process. The answers provided by the interviewees have 
been entirely transcribed, resulting in 62 pages of text. The duration differed from 38 minutes 
to 74 minutes, with an average time of 56 minutes. The survey sent followed the script used to 
do the interviews and it consists in a document with a brief explanation of the study and six 
pages of questions (Exhibit 20). 
Table 1 translates the verified sample used to perform the analysis. For each innovator 
information is provided regarding the country of birth and the country where the solution was 
firstly implemented, the innovator’s type of need and its personal details (current age and 
gender). The code given for each solution follows Habicht et al. (2012) division regarding the 
different contexts in which patient innovators innovate. Group A includes all innovations that 
emerged from “dead end situations”, group B contemplates innovations regarding “strong 
constrains on the daily life”, and group C includes cases of innovations which occurred in 
“rare conditions” contexts. This last situation is not verified in our sample, due to the 
inexistence of cases comprising the characteristics of rare conditions. The following coding 
section explains these attributes in more detail. 
The final sample consists in 15 solutions from 13 different countries, where six 
innovators were patients (A1, A6, A7, A8, A10, B3), five caregivers (A3, A5, B1, B2, B4), 
and three collaborators (A2, A9, B5). Solution A4, is the result of a collaboration between a 
patient and caregiver. 
Code Country of birth 
Country of 
innovation Type Age Gender Solution Picture 
A1 Burundi Burkina Faso Patient 39 Male 
Malaria 
prevention soap 
 
A2 Chad Chad Collaborator 33 Male 
Health 
monitoring 
platform 
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A3 Ghana Ghana Caregiver 33 Male Blood donation platform 
 
A4 Senegal and Cameroon Senegal 
Patient/ 
Caregiver 
24 
and 
23 
Male 
and 
Female 
Blood donation 
platform 
 
A5 Uganda Uganda Caregiver 26 Female Pneumonia detection shirt 
 
A6 Uganda Uganda Patient 24 Male Malaria testing device 
 
A7 Tanzania Tanzania Patient 40 Male Low cost water filtration system 
 
A8 Philippines Philippines Patient 48 Male Blood donation platform 
 
A9 USA Haiti Colaborator 
40 
and 
40 
Male 
and 
Female 
Reusable diapers 
 
A10 Nigeria Nigeria Patient 51 Male Urine Malaria Test 
 
B1 Rwanda Rwanda Caregiver 23 Male Low cost hand bike 
 
B2 Tanzania Tanzania Caregiver 31 Female 
Malnutrition 
monitoring 
platform  
B3 India India Patient 35 Male 
Chronic diseases 
monitoring 
platform  
B4 Pakistan Pakistan Caregiver 23 Male 
Tremors 
monitoring 
platform  
B5 USA Sudan Colaborator 47 Male 3D Printing Arm 
 
Table	1	-	Verified	Sample	of	user	innovators	
3.5. Coding	
Lüthje et al. (2005) in the study of innovations developed by mountain bikers, concluded 
that users with a problem are compeled to develop solutions, because they possess local need 
information. In the same study, the impact of local technical knowledge on innovations was 
analysed, revealing that  users already  have the required  knowledge to  develop a technical 
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solution. Knowing this, we started to code the solutions accordingly to the type of need a 
patient had, or still has, and the knowledge a user owns to develop a solution. 
Habicht et al. (2012) distinguishes among three types of situations: dead end situations, 
when patients face scenarios where there is no hope of making progress regarding their health 
condition (e.g., fatal diagnosis); strong constrains on daily life, when “patients cannot escape 
their situation”, living with their health disorders permanently. At last rare conditions, health 
disorders that affect a small portion of people worldwide. Rare conditions are considered 
niche markets, where there are no commercial incentives, and less investment for innovation. 
Two more codes were added within this coding, in order to transcribe the sub-category 
Local Environment. Firstly, the limited professional expertise (Dreier, 2016), meaning a user 
perceives the lack of knowledge given by health professionals, either to explain the condition 
or to treat patients in a correct manner. Secondly, we have included characteristics of 
developing countries (DePasse et al., 2016), where a user acknowledges the unique 
constraints within his/her community. 
Afterwards, we coded our sample based upon local technical knowledge, encompassing 
the following drivers: enjoyment of the innovation activity (Lerner & Tirole, 2002; Lakhani & 
von Hippel, 2003), enhanced reputation that may flow from making high-quality 
contributions (Lakhani & von Hippel, 2003) and greater level of experience and expertise 
with a given product (Lüthje, 2004; Kuusisto et al., 2013). 
Table 2 sums up the different drivers that led patients, caregivers, and collaborators to 
innovate. 
Category Sub-Category Driver Reference 
Local need 
information 
Disease motivated 
Dead end situations 
Habicht et al. (2012) Rare conditions 
Strong constrains on the daily 
life 
Local environment 
Limited professional expertise Dreier (2016) 
Characteristics of developing 
countries (DePasse et al., 2016) 
Local technical knowledge 
Enjoyment of the innovation 
activity 
Lerner & Tirole (2002); 
Lakhani & von Hippel 
(2003) 
Enhanced reputation that may 
flow from making high-quality 
contributions 
Lakhani & von Hippel 
(2003) 
Greater level of experience and 
expertise 
Lüthje (2004); Kuusisto 
et al. (2013) 
Table	2	-	Coding	for	Drivers	in	user	innovation	
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We also have coded our findings regarding the existent complementary assets required 
for commercialization. According to Teece (1986), a complementary asset is what provides an 
innovation with the necessary services so that it can become commercialized in a successful 
manner. In line with this, a complementary asset is seen as a different asset from the core 
solution, which increases its value (Teece, 1986). 
Innovations created by users generally have a narrow access to this kind of assets 
(Agarwal & Shah, 2014). After-sales support, distribution channels, marketing, competitive 
manufacturing, human resources and complementary technologies are examples of 
complementary assets given by Teece (1986) and Svensson (2007). 
Considering this, we adopt the following line of coding to classify our sample (Table 3). 
Code Sub-code Reference 
Complementary assets 
After-sales support 
Teece (1986); Svensson 
(2007) 
Distribution channels 
Marketing 
Competitive manufacturing 
Human Resources 
Complementary technologies 
Table	3	-	Coding	for	Complementary	Assets	
 
 
 
4. Results	
In the following chapter, we present the most important drivers, the socio-economic 
factors that influenced the creation and development of the innovations, and the 
complementary assets that contributed to the commercialization of the solutions under 
analysis. 
4.1. Drivers	in	healthcare	across	developing	countries	
4.1.1. Local	need	information	
As mentioned before, and according to the literature, this driver is divided in different 
types of needs. For each type, we provided quotes from the interviews that supported our 
classification. 
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4.1.1.1. Dead	end	situations	
Ten solutions came from users that lived closely with near dead situations (from A1 to 
A10). 
“I almost died from malaria while doing my military service in Burundi, where I 
was almost left for death because of malaria (…)” (A1) 
“(…) the parasite can enter in the penis and then small worms are created in the 
system and when people urinate came with blood. Schistosomiasis is really 
painful for kids when they urinate.” (A2) 
“She started with normal headaches and then started to be complicated. She 
started to spend the entire days in her bed and stopped doing things by her.” 
(A3) 
“I lost a lot of blood when I had my accident, the diagnostic was if we cannot 
find a blood donor, I could not move my leg, I could die.” (A4) 
“(…) after her grandmother fell ill, and was moved from hospital to hospital 
before being properly diagnosed with pneumonia.” (from http://bit.ly/2klAnJG 
on 17.05.2017) (A5) 
“I have always lived with malaria as I was growing up. But it was when I had 20 
years old that suffered more severely, living with malaria for 2, 3 weeks.” (A6) 
“After the doctor diagnosed me several water-related diseases and, besides 
giving me medicine, I was told to wash my hands with soap. I need to change my 
life style (…)” (A7) 
“My platelet level was already in a critical condition, it was already 90.000 and I 
think the recommended platelet level is 450.000 and 500.000.” (A8) 
“(…) they are uneducated and they are living in very very dangerous situations 
when it comes to sanitation.” (A9) 
“Having grown up in Nigeria, (…)	 contracted	 malaria	 multiple	 times	 from	 a	
young	age.” (from http://bit.ly/2r4KrvX on 27.05.2017) (A10)	
4.1.1.2. Strong	constrains	on	the	daily	life	
Five innovations were triggered by imposed limitations throughout their lives. Two 
consisting in a physical disability (B1, B5) and three regarding chronic diseases (B2, B3, B4). 
“(…) it was very hard for his uncle to leave the house because he had a 
wheelchair but that type of wheelchair actually needed someone to push it.” (B1) 
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“Lots of my friends and family are overweight and obese, with hypertension and 
diabetes. And people close to my family have babies that are undernourished.” 
(B2) 
“(…) I started to understand how chronic health conditions are poorly managed 
in India. I realised that in our country, the chronic care management is not 
extended beyond the hospitals or clinics.” (B3) 
“He did not use to move that much, he was still able to drink stuff but he had to 
reduce some actions and eating was a bit bad, eating bread was easy for him but 
eating anything like soup or like rice was a bit difficult.” (B4) 
“Seeing this 12-year-old boy, who lost both of his arms and see this boy who 
would rather be dead, than live with no arms and be a burden to his family.” 
(B5) 
4.1.1.3. Limited	professional	expertise	
In this category, patients, caregivers and collaborators perceived the necessity to create a 
solution that could assist patients to receive a better treatment or a better monitoring (A2, A8, 
A9, B1, B3, B4). The following quotations provide examples of this driver: 
“(…) (nurses) they really do not have time to talk about the disease, they do not 
know how people contract the disease (…)” (A2) 
“It is just the basic information and another thing is that there is no medicine for 
dengue, all they have is just to administer some injections and medicines to help 
you fight, or get me in a condition to be able to fight the disease.” (A8) 
“Even if they get the disease and they go and see a doctor, the likelihood of that 
doctor having the proper medication is about 10%.” (A9) 
4.1.1.4. Characteristics	of	developing	countries	
User innovators stated they were aware of their surrounding environments and the fragile 
conditions in which they live (A1, A2, A3, A4, A6, A7, A8, A9, A10, B1, B2, B3, B5). 
“My village was far away from hospitals and at night people from the village had 
to carry me with their own hands to the closest hospital.” (A1) 
“In the village, they do not have a laboratory, so they did not know that he was 
suffering from schistosomiasis.” (A2) 
“Here in Ghana, there was always a complaint for blood and not very much was 
happening.” (A3) 
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“(…) she had to go every month to a hospital to receive blood transfusions, until 
she stopped receiving this treatment because of a blood shortage in the hospital.” 
(A4) 
“Generally, in Uganda, a person can catch malaria 2 or 3 times a year (…)” 
(A6) 
“These problems are seen as a part of life, I lived with these problems since 
always because my parents did not have much money and in Tanzania the bottled 
water is very expensive.” (A7) 
“Not all people in the Philippines know their blood type.” (A8) 
“What is happening is that faecal matter is getting into the water or is getting 
into the homes, causing the deaths from water.” (A9) 
“How do we detect malaria easily?  Most rapid blood tests are difficult to use. A 
simple non-invasive test was critically needed.” (A10) 
“The rural areas make so hard for the populations to get access to wheelchairs 
that can be used in those rural areas (…)” (B1) 
“Many families especially in rural communities associate chronic malnutrition as 
shame or witchcraft so they delay seeking for medical help.” (B2) 
“One of the things of course is that doctors in India are very busy.” (B3) 
“I think the major driver was when I realized that Daniel was a victim of war, he 
was an innocent boy whose life was completely shattered for something that he 
had no control over.” (B5) 
4.1.2. Solution	related	knowledge	
Taking into account the stickiness of information on the user’s side, innovators 
increasingly depend on “local solution information” (Lüthje et al., 2005). 
4.1.2.1. Enjoyment	of	the	innovation	activity	
Three user innovators stated they had performed their solutions either by fun or to 
increase the required knowledge associated to the solution (A3, A6, B5). 
“I love technology so I would like to use technology to solve.” (A3) 
“I lived with this health disorder and I love technology.” (A6) 
“Could go and helped him and print him an arm, make his life in anyway better, 
that was the driving force.” (B5) 
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4.1.2.2. Enhanced	reputation	that	may	flow	
Seven user innovators highlighted how their reputation was recognized by the 
communities they are living in (A1, A2, A4, A5, A8, A9, A10). The following quotations 
serve as illustration for this driver: 
 “The winning of a national prize in 2015 from an NGO Reach for Change, that 
enabled us to have more recognition.” (A4) 
“(…) has been short-listed for this year’s Royal Academy of Engineering’s 
Africa Prize (…)” 
(from http://bit.ly/2pX4mJt on 18.05.2017) (A5) 
“Since then achieved the 2nd place at the Social Innovation Camp Asia, in 
Malaysia. 2nd place at Microsoft’s Apps for Asia, and because of that we were 
able to exhibit the application back in 2013 in New Deli, India. And just recently, 
last December, we just received an acclamation award by our department of 
health, by the Philippine blood center.” (A8) 
4.1.2.3. Greater	level	of	experience	and	expertise	
The level of experience and expertise has a positive relation with the creation of solutions 
by user innovators, adjustable to them or their peers (Lüthje, 2004; Kuusisto et al., 2013). We 
found two cases where user innovators made use of their expertise (A7, B1). 
“I studied about nanomaterials for about seven years, and my PhD thesis focused 
on how to put this component on a filter (…)” (A7) 
“After completing his vocational training, he thought of something to help his 
community and to offer them the possibility to afford a wheelchair.” (B1) 
4.2. Existent	socio-economic	factors	in	developing	countries	
The verified socio-economic factors across the existent countries in the sample are 
seldom comparable with the ones observable amongst the developed nations. 
4.2.1. Healthcare	
During the interviews, 13 user innovators made references to the fragile state of the 
healthcare system of the countries where innovations occurred (A1, A2, A3, A4, A7, A8, A9, 
A10, B1, B2, B3, B4, B5). The following quotations present examples of problems involving 
this socio-economic factor: 
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“Hospitals are inserted in strategical areas, not accordingly with diseases, but 
given the terrorist attacks.” (A1) 
 “Very poor, very poor, Senegal is a poor country so there are a lot of problems 
in healthcare.” (A4) 
“(…) these days the government is trying to spread. But sometimes there is just a 
building, there are no doctors or nurses and no medicine.” (A7) 
 “(…) it is the worst situation that I have ever seen, the medical situation in Haiti 
is horrible, is terrible, it is what you see on the news.” (A9) 
 “There is Abajyanama b'ubuzima (or health advisers) at every village, making 
easier to connect patients to first aid, but very few specialized medical personnel 
in Rwanda and to get in contact with them is very difficult (…)” (B1) 
“A common problem is on the number of doctors or caregivers in relation to 
people available.” (B2) 
4.2.1.1. Access	to	pharmacies	
Five innovators reported the access to pharmacies, as well as the level of prices charged, 
constituted a major obstacle for them (A2, A6, A9, B3, B4). Examples of problems in this 
type of access were described in the following quotations: 
 “People have good access to pharmacies, but they will not have what you need 
(they will have aspirins, they probably have antibiotics, but will not have 
medicine for specific diseases) and they cannot afford it (…)” (A9) 
“If patients cannot afford, they will not take the recommended medicine.” (B3) 
“Currently in Pakistan, there is not a broad access to pharmaceutical drugs for 
this particular disease, only one or two medicines were available, whereas on 
other parts of the world the range is enormous.” (B4) 
4.2.2. Environment	
Two user innovators highlighted the sense of community, which played an important role 
in the innovation process (A2, B1). 
“The community was very important to the project because when we were at the 
villages we tested in the community.” (A2) 
“The conversations he had with several innovators gave him the confidence he 
needed to develop the solution.” (B1) 
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4.2.2.1. Access	to	potable	water	
The lack of access to potable water is present in user innovators’ statements, two 
solutions aim to tackle the problem of contaminated water in two different ways and countries 
(A7, A9). 
“(…) even today in Tanzanian rural areas and congested cities there is a lot of 
struggles because of lack of clean water, among the poor communities.” (A7) 
“(…) there are accesses where they installed water systems in some communities 
but the majority of the water is polluted.” (A9) 
4.2.2.2. Corruption	
Corruption represents a relevant problem amongst these countries, and two user 
innovators have faced troubling situations (A8, A9). “Because	 donors,	 let’s	 say	 if	 this	 patient	 is	 already	 in	 this	 scenario	 where	 he	
really	needs	blood,	so	as	much	as	possible	they	can	actually	ask	let’s	say	10.000	
pesos,	you	know?	It	is	corruption.”	(A8)	“Customs	 in	 Haiti	 is	 like	 dealing	 with	 the	 IRS	 (laughs),	 there	 are	 lots	 of	
corruption.	 It	 is	horrible,	 the	people	who	go	 to	 try	 to	help	 the	country,	are	 the	
same	 people	 from	 who	 they	 try	 to	 get	 advantage.	 And	 that	 begins	 with	 the	
Haitian	government.”	(A9)	
4.2.2.3. War	
One user innovator described the war climate experienced in the country and underlined 
this as a major obstacle (B5). 
“You have a lot of kids like him, who can go to school but it is very difficult 
because of the war that is going on, and because of the bombings, and because of 
the general turmoil.” (B5) 
4.2.3. Education	
Although user innovators described the difficulty of having access to a higher educational 
degree in their countries (A9, B2, B5), they also considered that education played an 
important role on their solutions (A4, A6, A8, B1), two user innovators reported problems but 
mentioned the importance of education (A2, B4). Descriptions of both the problems and the 
importance that education had for their solutions are provided in the following quotations: 
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“Yes, because our studies gave us technical knowledge to build the platform 
without external support.” (A4) 
“The access to a University degree from the Makerere University, in Uganda, 
enabled me to have a better understanding on technological software, which 
proved to be highly important.” (A6) 
“High school is an honour and a privilege, it is not a right!” (A9) 
 “(…) they do have schools, Daniel is now 18 and he reads at a fourth-grade 
level, they do have primary schools but you have a lot of kids that are in the 
system intermittently.” (B5) 
4.2.3.1. Access	to	complementary	facilities	
In addition to the importance of university, four user innovators benefited from other type 
of facilities, enabling them to develop their solutions (A4, A6, B4). 
“Yes, it is very important because at the beginning of the project we have a lot of 
problems in terms of money, in terms of logistics and we need good computers to 
build a platform.” (A4) 
“(…) the access to a design studio to start building his idea was very helpful.” 
(A6) 
“(…) I had access to one of the best laboratories here in Pakistan for the 
development of the hardware, but generally this is not the case.” (B4) 
4.2.4. Technology	
Nine innovators revealed that the access to technological services proved to be 
fundamental throughout the stages of innovation processes (A1, A2, A4, A6, A7, A8, A9, B3, 
B4). Six examples of the importance and the difficulty to have access to technology, in order 
to develop user driven solutions: 
“Without it we could not work and contact our partners, we are using like mails, 
also we call people using Whatsapp or Skype (…)” (A1) 
“It is not really possible to use high technology in Chad.” (A2) 
 “In Uganda, the price of internet is excessive and the use of smartphones by the 
population is low, and does not offer a good speed in relative terms.” (A6) 
“In rural areas people do not have electricity, so do not have internet.” (A7) 
 “The access to mobile connection is great, more people have access to cell 
phones than they have to toilets. It is very important, for safety purposes in 
remote regions (…)” (A9) 
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“Internet connection is having a lot of infrastructure problems, the methods to 
connect are primitive, leading to a poor smartphone integration, which Indian 
population did not perceive yet as a user-friendly software.” (B3) 
4.3. Complementary	assets	
Organizations have an increasing need to diversify their complementary assets, due to the 
complexity in terms of resources and capabilities needed for commercialization (Lin & Wang, 
2015). All the solutions in our sample show the presence of at least one complementary asset. 
4.3.1. After-sales	support	
The service provided by these user innovators, after the diffusion to other patients, is an 
essential tool to increase value for the innovation. Five user innovators provided a description 
of how they are providing a post-sale help (A3, A9, B1, B2, B5). The following quotations 
are examples to show a description of this complementary asset: 
“(…) so now we have a health call center and users leave a message and the 
health professionals will respond later.” (A3) 
 “(…) he is able to create wheelchairs that are able to adapt the need, he can 
adjust the wheels to afford the weight it can carry.” (B1) 
“Apart from the platform that is still under development, Afya Slices organize 
seminars for mother, housemaids and caregivers on maternal and children 
optimum nutrition care and practices.” (B2) 
4.3.2. Distribution	channels	
Three user innovators provided a description of how they benefit from having access to 
other channels, aiming to reach end-users (A6, A8, A9). Description examples of this 
complementary asset are provided: 
 “Just recently the Filipino blood center contacted me to work together and to 
adapt Blood Donors Network to hospitals.” and “We were able to put in each 
health centers independent coordinators, responsible for a given region and his 
donors (…)” (A8) 
“(…) we are looking to scale up the sale to organizations, people traveling to 
other countries can take DriButts with a special rate and deliver them there.” 
and “To bring DriButts to the masses they teamed up with a company called (…) 
to have the diapers mass produced in China.” (from http://bit.ly/2qpCQW0 on 
18.05.2017) (A9) 
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4.3.3. Marketing	
Nine user innovators provided a statement showing they are already interested in 
promoting and/or selling the solution to other users (A1, A3, A4, A6, A7, A8, A9, B1, B4). 
Five examples of quotations by user innovators describe this complementary asset: 
 “We do a lot of street marketing in Senegal, like distributing flyers for 
presenting the platform for people.” (A4) 
 “(…) we will start to export to around 20 countries (…)” (A7) 
“(…) this year will be launched in media, stakeholders, everything.” (A8) 
“(…) a diaper costs $15 and you pay $30 to give another to developing 
countries.” (A9) 
 “The solution was diffused on the KickStarter (a crowdfunding platform) 
webpage.” (B4) 
4.3.4. Competitive	manufacturing	
Four user innovators highlighted they had benchmarked their competitors and identified 
unique characteristics in their solutions, that would give them market advantage (A7, A10, 
B1, B4). 
“There are filters but they do not solve the problems comprehensively, some 
filters remove chloride but no the bacteria and others do not have a customer 
service.” (A7) 
“The other solutions were not simple to use.” (A10) 
“A patient is now able to use its hands rather than the legs to move, this is the 
main difference from the imported wheelchair.” (B1) 
“The available products have to be imported, mainly from the US, which 
increases the price.” (B4) 
4.3.5. Human	resources	
Seven user innovators showed involvement when choosing the adequate team for the 
development and commercialization of the innovation (A1, A3, A4, A8, A9, B3, B4). The 
following quotations are examples to show a description of this complementary asset: 
“(…) the team is working with partners around the world.” (A1) 
”At this moment we are starting to have many ambassadors in rural areas (…)” 
(A4) 
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“I am working alone on this project, but I have a team of consultants to help with 
the development of the application, an office to work on the legal side of the 
application and I also have some sales consultants to help me out in regards to 
the commercialization of the application.” (A8) 
“(…) we establish leaders in all the regions, in charge of managing all the 
contacts around the country. That person manages and educates, is responsible 
for all the existent diapers in one community, for proper use, to make sure they 
are throwing the poop to the water.” (A9) 
”(…) the constitution of an agile team are equally important.” (B3) 
“One of the really beneficial things was having a good team (…)” (B4) 
4.3.6. Complementary	technologies	
The functioning of the innovation aligned with other technologies is also relevant to increase 
the value. Ten user innovators showed signs of incorporating this type of asset (A1, A2, A4, 
A5, A6, A7, A8, B1, B3, B5). Description examples of this complementary asset are provided 
in the coming quotations: 
 “We have regular radios, but never used them for raising awareness, then they 
asked us if those areas have radios and after that we saw that populations use 
radios and started using.” (A2) 
“(…) we also have a web platform, which do the same, we have an SMS alert to 
when there is an emergency, we can push an SMS for notification through our 
platform users.” (A4) 
"The processed information is sent to a mobile phone app (via Bluetooth) which 
analyses the information in comparison to known data so as to get an estimate of 
the strength of the disease (…)"(from http://bit.ly/2r7e91A on 18.05.2017) (A5) 
“That is the reason why I started to think in changing the approach and cover 
also the desktops.” (A6) 
 “(…) we have also developed an in-app messaging system in our solution like 
Facebook and Viber, so users already have the option to use one of the two 
systems.” (A8) 
4.4. Reverse	Innovation	
In order to study the potential of these solutions in developed countries, we asked three 
physicians with expertise in the patient innovation field to review and classify our sample. 
We divided the classification in the following three levels (table 4): 
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Level Description Color Solutions 
1 
Solutions potentially adoptable by developed 
countries 
Green A10, B4, B5 
2 
Solutions can be adopted if user innovators apply 
changes 
Yellow A6, B2 
3 
Solutions do not have the potential to be adopted 
by developed countries 
Red 
A1, A2, A3, A4, A5, 
A7, A9, B1, B3 
Table	4	-	Reverse	Innovation	classification	
In addition, exhibit 22 summarizes the excerpts from these external evaluators. 
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5. Discussion	and	Conclusions	
To the best of our knowledge, this analysis is the first of its kind, which on one hand is 
the major motivation for our dissertation, but on the other hand constitutes a limitation in the 
sense that unable us to compare with similar literature and verify the correct applicability of 
the study. 
Certain limitations arose during the research, either because of the nature of the study, or 
due to the geographical area analysed. Lastly, we provide advices on where to direct the 
coming research, aiming to offer a more extended available literature on this topic. 
5.1. Hypothesis	
After the conducted interviews, we started to perceive there are differences in the type of 
needs patients have, comparing to developed countries. Knowing this, we formulated the 
following hypothesis: 
H1: Despite the similarities on the user innovation process between regions with a 
contrasting development level, the triggers to innovate may differ. 
Our second hypothesis raising, regarding solutions developed by these users that aim to 
overcome a general need and not just a need of a single patient. By being close to their 
community, the innovator ends up fulfilling not only his need, but the needs of his 
community. 
H2: User innovators across these regions try to overcome not just their personal needs but to 
solve existent needs in their communities. 
We verified that 33.3% of user innovators participated in incubator programmes, either 
offered by NGOs (A2, A3, A4, B2) or by governments (B1). In addition, we verified that both 
private organizations and foundations, such as Microsoft and Bill and Melinda Gates 
Foundation, designed programmes in form of contests, to reward solutions invented by user 
innovators with the intent of improving the quality of life along their communities.  From our 
sample, 60.0% of user innovators were awarded by organizations and/or foundations. This led 
us to another hypothesis: 
H3: Support given by organizations and foundations from the developed world are also 
oriented towards user innovators in developing countries, and the access to incubator 
programmes is seen as a useful tool to develop and promote social entrepreneurship. 
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5.2. Outcomes	
5.2.1. Patient	innovators	in	developing	countries	
Throughout the research, we observed a strong evidence of patient innovation along 
developing countries. Supported by the available literature to which we had access to, we can 
complement our answer to the research question regarding the drivers that users have to 
innovate in a context of higher need, when comparing with developed nations. 
Table 5 illustrates the percentage of each considered driver present in our sample, from 
which we can validate the findings of Hipp and Grupp (2005) and Utterback (1974), 
regarding innovations being stimulated by market needs, rather than technological 
opportunity. User innovators are triggered, in a higher proportion, by the lack of solutions 
available on the market. 
Category Sub-Category Driver  
Local need 
information 
Disease motivated 
Dead end situations 10 (66.7%) 
Rare conditions 0 (0.0%) 
Strong constrains on the daily life 5 (33.3%) 
Local environment 
motivated 
Limited professional expertise 6 (40.0%) 
Characteristics of developing countries 13 (86.7%) 
Local technical knowledge 
Enjoyment of the innovation activity 3 (20.0%) 
Enhanced reputation that may flow 7 (46.7%) 
Greater level of experience and expertise 2 (13.3%) 
Table	5	-	Results	for	Drivers	in	User	Innovation	
Note: In regards to the sub-category “Local environment”, we verified that some user innovators had more than one driver that led 
them to develop a solution. In regards to the category “Local technical knowledge”, some user innovators did not have this type of drivers to 
develop a solution. Reasons why the sum of each one is not 100%. 
This partially confirms the first hypothesis raised, roughly 67% of user innovators in our 
sample had as trigger dead end situations and none of them faced a rare disease condition, 
contrasting with other studies on developed regions, like Shcherbatiuk and Oliveira (2012) 
and Oliveira (2014), which covered rare diseases. 
In addition, we verify that 86.7% of the analysed user innovators were triggered by the 
state of their countries, like the distance to hospitals, inadequate hygiene habits, or lack of 
knowledge about the blood donations.  
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5.2.2. Socio-economic	conditions	
Amongst the socio-economic conditions of each environment under analysis, user 
innovators highlighted three of them. Firstly, healthcare conditions, where 86.7% of user 
innovators consider there are problems in both the delivery of healthcare services and the 
access to pharmacies. 
The second condition regards problems accessing education and its importance, 
mentioned during 60.0% of the interviews. Six user innovators indicated that education was 
important for the development of the solutions, and two of these referred problems in this 
access. Another three user innovators, made a reference to the existing problems in the 
educational systems but did not consider education important for their solutions. 
Evidence corroborates findings from Van der Boor et al. (2014), listing the major socio-
economic contributors to innovations in developing countries, where access to ICT is 
included. In this category, 9 user solutions were studied (60.0%), 44.4% mentioned problems 
related with access to technologies. While, 55.6% referred the importance to have this access 
for their solutions. 
Although a lower number of user innovators made allusion to the surrounding 
environment (40.0%), it is also important to analyse. The importance to have a community 
offering help was present in two dialogues, while other two user innovators mentioned 
problems in water quality. The problem of corruption was referred by two user innovators 
(one of these also talked about the lack of access to potable water, A9). At last, one user 
innovator (B5) mentioned war as one of the major existing problems. 
Figure 3 displays the number of user innovators for each socio-economic factor 
considered relevant to mention them during the interviews and surveys. 11 user innovators 
mentioned more than one socio-economic factor, 3 mentioned only one (A3, B2), and a user 
innovator (A5) did not referred any one. 
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Figure	3	-	Results	for	Socio-economic	factors	
5.2.3. Patient	innovators	as	entrepreneurs	
Through a study across organizations and industries, Helfat and Lieberman (2002) 
discovered that complementary assets, for new entrants, are more relevant than their core 
resources. Owning specialized and/or co-specialized complementary assets, enables firms to 
create value and prevent imitators to take profits from them (Teece, 1986). 
There are two complementary assets in which user innovators invested more: 
complementary technologies and marketing. Complementary technologies that help 
increasing the solutions’ value are present in 66.7% of these user driven solutions. On the 
other hand, 60.0% of user innovators are spending time and financial resources in marketing, 
to promote and sell their solutions. 
With a lower relevance, 46.7% of the analysed solutions shown a concern for choosing a 
good team. We find solutions that benefit from having an after-sales service in 33.3% of the 
solutions, and others are aware of other available solutions, offering distinctive approaches 
(with 26.7%). Moreover, 20.0% of the sample’s solutions established, or planning to 
establish, a distribution network to increase the value for the solution. 
Figure 4 presents a summary on the complementary assets considered most important for 
user innovators. 
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Figure	4	-	Results	for	Complementary	Assets	
Table 6 exposes a high percentage of user innovators that decided to create their own 
company to take advantage of the available complementary assets and commercialize their 
solutions. 
 
Created company 13 (86.7%) 
Did not create 2 (13.3%) 
Table	6	-	Results	for	creation	of	companies	by	user	innovators	
Of those two user innovators that decided not to create a company, one of them was 
already employed in a company and decided to continue in that same company (A6). 
The other user innovator could not create its company due to lack of funding (B4). This 
finding is important, because our sample of 15 innovators is considered limited and more 
users might face barriers like this, across developing countries. 
“Basically the main issue were financials because currently there are not many 
investors in Pakistan that spend money on healthcare products (…)” (B4) 
Table 7 sums up the findings that support the conclusion retrieved by Lin and Wang 
(2015), when argued about a positive relationship between the capacity an organization has to 
create innovations and to have complementary assets, with the introduction of patents. 
Although the sample size is limited, we found 40.0% of user solutions with their IPR 
protected, while 26.7% are waiting for approval to protect. Moreover, there are 33.3% of user 
innovators that prefer not to protect their IPR. B4 terminated the project without protecting 
the solution. 
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IPR protected 6 (40.0%) 
Waiting for approval 4 (26.7%) 
IPR not protected 5 (33.3%) 
Table	7	-	Results	for	IPR	protection	
5.3. Reverse	Innovation	
From the sample, we concluded that about 27% of the solutions could be adopted by 
developed countries, whilst other 6.7% might have use in these countries if another approach 
is followed. Table 8 sums up the evaluations provided by the two physicians as evaluators. 
 
Potential for adoption 3 (20.0%) 
Adoption might result, after changes 2 (13.3%) 
There is no potential for adoption 10 (66.7%) 
Table	8	-	Results	for	Reverse	Innovation 
5.4. Policy	Implications	
Healthcare stakeholders must recognize the importance of user innovations, as they are 
the ones facing the needs. Practitioners and policy makers across developing countries should 
facilitate the access to complementary assets needed by users to innovate and present new 
solutions to a market in need for more efficient medical devices (von Hippel, 2016). 
5.4.1. Medical	personnel	
There are cases in which medical support was not provided in a clear and efficient 
manner. Medical professionals must be aware of this phenomenon and share it with their 
patients’ communities, aiming to improve a sector that needs innovation, especially within 
these regions (O'Donnell, 2007). 
Practitioners should play a more proactive role and develop a closer relation with patient 
innovators, in order to guide and advise them along the innovation process. Whilst, patient 
innovators can use feedback to improve solutions, thus increasing the possibility of being 
used by others with similar health conditions. At last, digital health platforms offer the 
necessary conditions for the improvement of these relations. 
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5.4.2. Policy	makers	
Oftentimes, user innovators described a lack of awareness by the populations. Investment 
in educational tools and healthcare venues is of major importance to tackle deeply rooted 
problems amongst the communities. 
Digital health platforms such as Patient Innovation, contribute to patient innovators’ 
communities, by offering the possibility to diffuse their solutions, receiving feedback from 
their peers. In addition, these health platforms can serve as another way to engage medical 
professionals and provide more pertinent feedback on the available solutions. 
Another crucial policy is to offer conditions for user entrepreneurs to develop their 
solutions, by offering guidance to them, and favourable socio-economic environments, such 
as incubators and healthcare entrepreneurial contests. 
5.5. Limitations	
By applying a multiple case study analysis, our study comprises certain limitations. The 
case selection is included in the theoretical sample, constituting a limitation. As Eisenhardt 
and Graebner (2007) concluded, the cases chosen must contribute to the theory and not so 
much to the uniqueness of the case. 
Secondly, we obtained information on the cases mainly through national newspapers. 
Given the developed nature of the analysed countries, there may exist other patient innovation 
cases, not successfully implemented, which did not call media’s attention. 
The fact that several articles were not data accurate, also constitute a limitation, as the 
story beyond the innovation could be inaccurate, especially in collaborator’s cases. In line 
with this reasoning, some innovators initially did not understand the study’s aim, leading to a 
misrepresentation of the sample. Take B2’s example, initially she explained that created the 
solution because of her community, but after several messages she explained the major 
motivation to create it was the existence of overweight relatives. To overcome this limitation, 
specific questions were asked during the conversations and our focus was on facts, reducing 
information subjected to individual interpretations. 
Our sample comprises 36 solutions’ authors, of whom 32 were contacted, yet only 21 
have replied (response rate of 65.6%), within these, only 15 make part of the study. A 
considerable number of user innovators did not reply to our contact, whilst the remaining ones 
scheduled interviews but were not able to conduct them. Moreover, due to the current social 
conditions in certain analysed countries, a call had to end up earlier because the interviewee 
was in an area where gunshots were being fired. In addition, during the interviews, the 
language used was English and sometimes this was hard to deal with. As example, there was 
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a user innovator who could not speak English, so we had to ask for help with the translation to 
a journalist. 
Interviewees’ bias is also considered a limitation, they may have used self-reported data, 
which is subjected to imprecision or misleading information. As mentioned by Eisenhardt and 
Graebner (2007), in a health-related context particularly, social desirability is seen as a 
concern, in the sense that can lead to altruism overstatements. To minimize this bias, data 
available from online sources, such as previous interviews given by innovators, public talks, 
or media reports, have been consulted to corroborate our findings, and in some cases to clarify 
dubious aspects. 
In addition, patient innovators in these countries might not disclose their innovations, as 
they consider them unimportant for the community, or due to limited resources (38.9% of the 
analysed countries have less than 10 internet users per 100 people). 
Last but not least, our research focused on health disorders selected randomly, without a 
specific pattern, thus with other type of health disorders the results might have been different. 
5.6. Future	Research	
As other researches consider (Habicht et al., 2012; Oliveira & Canhão, 2014), this matter 
is not yet sufficiently explored. 
These findings have been formulated having a database of 36 solutions, therefore future 
studies should adopt a quantitative approach across less developed countries, aiming to frame 
a sturdier theory. 
Apart from studying the how and why patients, caregivers and collaborators innovate, it 
could be of great importance to inspect the role of medical personnel in the development of 
new products, services, or processes, within developing nations. 
We suggest that further explorations on this matter should also include non-successful 
solutions, in order to perceive the crucial complementary assets and what sort of diffusion 
actions users should adopt. 
The patient innovation concept and all the questions within this field have been 
approached from a managerial point of view. Our study also indicates organizational 
behaviors and psychological signs, therefore it would be of much benefit to embrace a 
multidisciplinary research approach, covering the psychological manifestations. 
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Exhibits	
Exhibit	1	- Gérard	Niyondiko	(A1)	
Gérard Niyondiko was born in 1978 and he is originaly from Burundi. He created Faso Soap, which 
was also started by Moctar Dembélé, however he left the project in 2015. Currently living in Burkina Faso, 
Gérard holds a University degree in Chemical Engineering, and decided to create this project while he was 
stil a student.  He  dealt  with  malaria  on several  occasions,  being the  most severe episode  when  he  was 
doing his military service. Moreover, his brother and sisters were almost left for dead due to the disease. 
Aiming to reduce the number of malaria cases, he decided to create Faso Soap as a prevention tool, 
to be used as a complement with other available products, protecting populations from malaria. Consists of 
a mosquito repelent solution made with natural ingredients, providing an accessible, low-cost anti-malarial 
tool.  This soap is  made from shea  buter, lemongrass  oil and  other ingredients.  The respective tests are 
being made along with the Ministry of Health, providing a laboratory, and the Medicine Research Center. 
The team also  has some  partners around the  world (mainly in  France), aiming to increase the access to 
technical know-how and technologies. 
The main project target consists of continuing the tests on efficacy, aiming to get the approval by the 
WHO (to finance the  project) and, then starting the introduction in the  market.  Gérard  mentioned the 
importance of finding the necessary natural raw materials. From the 214 milion cases of malaria each year, 
90%  of them  occur in  Africa, accordingly to  Gérard, thus the  main target  of the solution are these 
populations. 
 Team: Gérard Niyondiko, Lisa Barutel and Franck Langevin 
  
Pictures	1	–	Faso	Soap,	by	Gérard	Niyondiko	
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Exhibit	2	- Didier	Lalaye	(A2)	
Didier Lalaye is from Chad, and was born in 1984. One day in 2014, he went to visit his parents’ 
vilage in Torrock (around 40kms away from his born town, in Pala) and visited a health center, where he 
found Simon, a 14-year-old child whose diagnostic was a urinary related disease. Simon was living with 
this health disorder and urinating blood for two years, and Didier discovered that schistosomiasis (spread 
by contact with fresh water contaminated with the parasites) affects more than 50% of children aged one to 
14 months of age, and found that there are health centers without a laboratory, making it impossible to run 
an accurate diagnosis. 
This led to the creation  of  DAWA  Mobile  Health, a  mobile  unit for  detecting and  manage 
schistosomiasis among rural vilages (given the distance to hospitals). By seting up laboratories in health 
centers and contacting target groups by telephone, patients take urine samples to their doctors and request 
their  diagnosis  via  SMS. Then  doctors analyse them and communicate  with  pharmacies to  prescribe 
medicine to patients. The results are given by SMS and those who are declared positive receive their drugs 
directly to their homes. 
Up  until  2017,  DAWA  Mobile  Health  diagnosed  more than  2,500 children and treated  more than 
600 patients with schistosomiasis, it has also alowed the population to have access to biological tests. 
  
  
Pictures	2	–	DAWA	Mobile	Health,	by	Didier	Lalaye	
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Exhibit	3	- MOJA	Team	(A3)	
The creator of MOJA was born in the year of 1984, in Ghana. He holds a University degree in 
Corporate Assignments and by the time of the creation of MOJA he was a freelancer. His sister was 
diagnosed with cancer, and needed a considerable amount of blood, as she lived with this health disorder 
for three months before passing away. 
The low levels of blood donation constitute a serious problem, particularly in Ghana. In 2015, only 
32% of blood was collected from donors (right now this level is situated around 48%) and it is used mostly 
(65% in Sub-Saharan African countries) in children under-5 years and pregnant women, that is the reason 
why MOJA was created. With 4,000 users, the cloud based app makes possible for National Blood Service 
to replenish its stock and contact interested donors, who have access to a national database of volunteer 
donors, to search and find their match for a blood transfusion. Donors are also encouraged to recruit their 
friends, earning points. 
After testing the app, the team realized that not a considerable size of Ghanaian population using 
smartphones, so they created a different approach. Medical staff is able to visit possible donors’ houses and 
collect blood. In order to keep blood donation in top of the patients’ minds, MOJA started to send health 
tips. 
The possibility to contact personally and 24/7 health professionals has been eliminated, because the 
team realized doctors and nurses were not able to serve that kind of direct demand, so now there is the 
possibility to leave a message and health professional will respond later. 
MOJA plans to cover other African areas such as, Nigeria, Liberia and Burkina Faso. 
  
  
Pictures	3	–	MOJA	App,	by	MOJA	Team	
 
	 	 53	
Exhibit	4	- Jean	Luc	Semedo	and	Evelyne	Ines	(A4)	
Jean  Luc  Semedo  was  born in  Senegal in  1993.  Whilst,  Evelyne Ines is  original from  Cameroon, 
born in  1994.  They  both  hold a  University  degree in  Telecommunications, and developed  HOPE: Mon 
Sang  Pour  Sauver  Des  Vies  during their studies. When  he  was five  years  old Jean  Luc suffered a car 
accident and he crucialy needed a blood transfusion to survive (this patient spent three months recovering 
in a hospital). Additionaly, Evelyne had a classmate back in Cameroon diagnosed with leukemia, which 
needed to  go to  hospitals to receive  blood transfusions every  month,  until  one  day she  went for the 
treatment and ended up by passing away, due to a blood shortage in the hospital. 
Considered as the first  digital  platform in  Senegal,  which  promotes  blood  banks and  blood 
transfusion centers to  mobilize their  donors.  Promotes  blood  donation  by registering  blood  donors and 
encouraging them to donate. The major goal is to provide information about the existent blood banks and 
emergencies occurring throughout the country. The platform is available in various local languages, aiming 
to increase the awareness  by local  Senegalese  populations.  Moreover, there is the  possibility to  use the 
application through SMS (to inform about the next donation date and about blood banks’ activities). 
During its eight-month pilot, HOPE was able to acquire around 10,000 users and the main target is 
to switch from the  pilot  program to the commercialization  phase.  This  phase involves an expansion into 
other countries, like Cameroon, Benin and Ivory Coast. 
They plan to create an ambassador’s program, to provide assistance and expand the project’s mission 
and vision through rural areas. This enables the project to take more advantages on the local languages. 
  
  
Pictures	4	-	HOPE,	by	Jean	Luc	Semedo	and	Evelyne	Ines	
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Exhibit	5	- Olivia	Koburongo	(A5)	
Olivia  Koburongo  was  born in  Uganda, in  1991. In June  2014, after  her  grandmother fel il and 
being moved from one hospital to another, before being properly diagnosed with pneumonia, passed away. 
With the help of a Telecommunications Engineer’s friend, Brian Turyabagye (born in 1993), and a 
team  of  doctors, she  developed  Mama-Ope (meaning  mother’s  hope).  Nowadays,  doctors simply  use a 
stethoscope to  detect  pneumonia,  which  has the same symptoms as  malaria, asthma,  or tuberculosis, 
making difficult to come up with an accurate diagnosis. “The time lost treating those rather than pneumonia 
could prove deadly for their patient”, as Brian mentioned during an interview. 
A  biomedical smart jacket, specificaly  designed for children ageing  between  0 to  5  years  old, 
enabling to distinguish pneumonia’s symptoms, like temperature, breathing rate and sound emited by the 
lungs.  Health  workers simply  have to slip the jacket  onto the child, and its sensors  wil  pick  up the 
symptoms.  Then, information is sent  via  Bluetooth to a  mobile app,  which analyses the information in 
comparison to known data in order to get an estimate on the strength of the disease. 
Mama-ope can diagnose pneumonia up to three times faster than a doctor and reduces human error. 
  
  
Pictures	5	–	Mama-Ope,	by	Olivia	Koburongo	
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Exhibit	6	- Brian	Gitta	(A6)	
Brian Gita is a Ugandan born in 1993, with a University degree in Computer Science, and a person 
with phobia of needles. He always lived with malaria as he was growing up, but it was when Brian had 20 
years old that suffered more severely, he lived with this disease for two to three weeks, which decreased his 
life productivity. Thus, he decided to develop Matibabu while working in an engineering company. 
The goal is to reduce the time for detection of malaria in a first stage (with Matibabu it takes less 
than three minutes, while the available products take about half an hour). Besides this, the patient wanted to 
change the way detection is done, avoiding the use of needles because of his fear and since it is a “painful” 
way to diagnose. 
The device works with the help of a smartphone. A patient simply inserts its finger into the clipper 
device and selects “start  diagnosis”  on the  phone.  The  device  makes  use  of light and  magnetism to 
agglomerate red blood cels and analyse the patient’s blood composition, then patients just need to wait for 
the diagnosis. 
Given the excessive  price  of internet in  Uganda and the low  use  of smartphones  by the  general 
population, Brian started to think in changing the approach and also cover the desktops. 
Since the  beginning  of the solution, four  prototypes  have  been  made and  Matibabu is  now in its 
testing  phase, from the  old  prototype to the  most recent,  he  decided to improve efficiency in terms  of 
sensitivity and accuracy when running the diagnosis. 
 
1st prototype 
 
2nd prototype 
 
3rd prototype 
 
4th prototype 
Pictures	6	–	Matibabu,	by	Brian	Gitta	
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Exhibit	7	- Askwar	Hilonga	(A7)	
Askwar  Hilonga is from  Tanzania and  born in  1977.  He  holds a  University  Degree in  Chemical 
Engineering from a South Korean University, where he developed an interest in nanomaterials. He lived 
with water related disease problems since always, because his parents could not afford botled water, a very 
expensive  product in  Tanzania.  He  wanted to reduce the  presence in the  water of  diseases like cholera, 
typhoid,  hepatitis  A and intestinal  problems, as in  Tanzanian  hospitals  50%  of  diseases are related  with 
poor water quality. 
The patient studied about nanomaterials for about seven years, and his PhD thesis focused on how to 
put a component made of this material on a filter combined with a slow sand filter. It is an integrated water 
purification system, a combination of slow sands and nanomaterials. 
He started by developing a prototype system in 2013, to test it amongst his community before taking 
it to the market. Afterwards he received financing to introduce Nanofilter® to a smal-scale market. 
Askwar  developed the filter and started seling it to  households (focusing  on  high and  middle 
income ones, and also providing water stations in remote poor communities). 
The changes from the first  prototype  have to  do  mainly  with  design,  he  decided to  build a  more 
atractive  product and is  now  working  with a company to come  up  with a  more  portable  product.  As  he 
mentioned during our interview, water quality is the same from day 1. 
Right now, a company is revolutionizing the design, and he is analysing the possibility of exporting 
to around 20 countries, including Colombia, Mexico, India and Sub-Saharan countries. 
According with March 2017’s report, the direct sales on high and middle income households were 
208 and the number of water stations was 150, up to our interview. 
  
  
Pictures	7	-	Nanofilter®,	by	Askwar	Hilonga	
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Exhibit	8	- Joel	Barquez	(A8)	
Joel Barquez was born in 1969 in Philippines, he is an active blood donor since 2002 (having done 
43 blood donations so far). He holds a University Degree in Technology Management and the creation of 
Blood Donors Network was his master thesis topic. 
On December 12th 1997, Joel got dengue, and the responsible doctor told him to contact friends and 
relatives in order to find a compatible donor for a blood transfusion. After seeking help from his close 
friends and relatives he discovered no one had the same blood type as his only two - three days later he has 
found a compatible donor, a neighbour, and was able to recover in eight to nine days. 
The patient created Blood Donors Network to overcome the inexistence of a database for patients to 
access the availability for blood transfusions, basically have a centralized blood bank system. It is a mobile 
application that provides a solution to help communities meet their blood supply needs by increasing the 
acquisition of new blood donors and establishing a network of donors, currently with 187 active blood 
donors in its database. 
Since its beginning the application has been pivoted, Joel does not want patients to contact directly 
donors because “that is where corruption comes in”, as much as possible he wants this process to be 
voluntary and non-remunerated. Therefore, customers started to be hospitals, health centres, Red Cross, 
corporate and university organizations, rather than the patients. Another added feature was the location 
option, in which an independent coordinator is responsible for a given region and his donors, offering them 
the necessary care and enables health centres to manage the donors’ database in an efficient way. 
  
  
Pictures	8	–	Blood	Donors	Network,	by	Joel	Barquez	
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Exhibit	9	- Michael	Wahl	and	Starla	Wahl	(A9)	
Michael  Wahl and  Starla  Wahl are  both  North  Americans and  were  born in  1977.  Michael  was a 
pastor and often went to do missions in Haiti, he started by helping to instal water filtration systems, along 
the poorest Haitian areas. While Starla is a nurse in the USA. 
It was during one of these missions that a mother caled his atention, he looked at her holding on to 
her naked baby and she recognized him. As he approached, she tried to remove the faecal mater from her 
baby, and  by seeing this  Michael realised that  mothers  do  not  know  how to remove  deadly  bacteria and 
parasites, and perceived the dimension of faecal related diseases in Haiti. Disposable diapers there are too 
expensive and mothers only use them when they leave the house to public appearances, so in 2013 Michael 
and Starla decided to create DriButs. “Education is what delivers the need” said him during our interview. 
Made out of a polyester spandex blend for the outer shel and the inner shel is a polyester lining, 
finaly there is an insert placed inside the diaper, made out of bamboo (naturaly resistant to bacteria). The 
diapers are fuly adjustable and fit to children up to three years old. 
Problems with supplying delays, led them to sew the diapers at their kitchen table, making around 
700  pairs  with a  help  of the couple’s friend, Jil  Auxford.  Each  diaper costs  $15 and they ask for  $30 
donations so that they can send  one  diaper to families in  need.  They are  now looking to  put “DriButs 
centers”  within the communities they are  present, and the  main  goal is to educate  parents about simple, 
proper  nutrition and sanitation classes (hygiene clean,  wash their  hands,  properly  dispose faecal  mater). 
Families are also taught to wash the diapers with soap and water and hang them up to dry, which should 
take about 40 minutes. 
  
  Pictures	9	–	DriButts,	by	Michael	Wahl	and	Starla	Wahl	
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Exhibit	10	- Eddy	Agbo	(A10)	
Eddy  Agbo  was  born in  Nigeria, in  1966.  He  holds a  University  Degree in  Biotechnology and 
currently lives in the United States, where he created Fyodor Biotechnologies Corporation. Since his early 
days, he contracted malaria back in Nigeria multiple times and doctors need to inspect a blood sample with 
a  microscope, to run the  diagnosis.  Besides  being a costly  process,  which also consumes lot  of time 
(usualy 30 minutes), this country suffers from medical shortage, making it difficult to treat a patient in the 
right manner at the right time. 
By  perceiving this,  Eddy created the  Urine  Malaria test, a simple  diagnostic test that  detects the 
presence of malaria using urine instead of blood. A “game changer in the management of malaria”, as he 
told us in the questionnaire. It consists in a dipstick test that tels within 25 minutes if the fever is due to 
malaria or not. By simply dipping the test strip into the sample cup with a few drops of urine the patient 
can know the diagnosis. If two lines show up then it is positive, if one line shows up it is negative, and if no 
lines show up then the test is invalid and must be repeated. This product only costs $2 per test, while the 
team is planning to reduce the cost per unit as production increases (ecoomies of scale). 
Eddy Agbo stated in our questionnaire that this kind of test is also very useful for travelers who visit 
endemic malaria countries. 
 
 
 
Pictures	10	–	Urine	Malaria	Test,	by	Eddy	Agbo	
 
 
 
 
 
	 	 60	
Exhibit	11	- Daniel	Habanabakyze	(B1)	
Daniel Habanabakyze was born in 1994 and he is from Rwanda. After dropping out from high school 
he decided to enter in a vocational training center. The caregiver could not provide either his uncle’s health 
condition or the diagnosis identified by the doctor, however his uncle was born with this type of physical 
disability and lived with it for about 50 years. 
He lived with his uncle, who could not leave the house, because he was not able to move his legs and 
could not afford a wheelchair or hire a caregiver, given the affordability restrains (the existent wheelchairs 
are mainly imported from China, and distributed at a cost per unit of about US$1,500, while in the US costs 
around US$500, accordingly with Wheelchair Foundationiv). 
Daniel  designed and constructed an affordable  wheelchair,  which  makes  use  of an electrical  part to 
respond to the patients’ chalenges (the wheelchair can be used by the patient itself, rather than depending 
on a person to push it). Patients are now able to use their hands rather than the legs to move. 
The caregiver started with basic tools to create a primitive electric wheelchair. Although he was not 
confident, he took it to the market and received valuable feedback to improve his solution. The next stage 
consisted mainly of adding some new features like other kind of wheels and beter chains, aiming to create 
a faster and smoother  wheelchair.  Nowadays,  Daniel is able to  differentiate and create  wheelchairs 
adjustable to patients’ needs, which varies with their weight. 
Although he stil needs more funds, Daniel is planning to expand to other districts, aiming to cover the 
entire country. In just a  year and a few  months, this caregiver  was able to sel almost  80  wheelchairs, 
mostly due to the adoption of an affordable approach. 
  
  
Pictures	11	–	Low-cost	hand	bike,	by	Daniel	Habanabakyze	
 
 
                        
iv	https://www.wheelchairfoundation.org/	
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Exhibit	12	- Neema	Shosho	(B2)	
Neema Shosho is from Tanzania and was born in the year of 1986. She holds a University degree in 
Food and Nutrition Sciences and by the time of Afya Slices’ creation she was a health nutritionist. 
Lots of her friends and family are overweight, with hypertension and diabetes’ problems. People close 
to  her family  have also  undernourished  babies. “These kids cannot  grow  wel,  both  physicaly  and 
cognitively, their immune system is  highly  afected  and,  as  a result, they  get sick  more  often”, said she 
while filing the survey. 
Afya Slices aims to address knowledge gap in nutrition in Tanzania. High prevalence of malnutrition 
is experienced in areas where people grow a lot of food, meaning that food availability is not necessarily 
translated into  good nutrition.  Moreover,  knowledge  on  optimum  nutrition  practices,  or  hand  washing is 
also very important. 
Thus, she decided to develop a mobile platform that wil educate communities especialy parents and 
caregivers (with the aim  of changing  negative  behaviours)  on  optimum  nutrition care and  practices for 
maternal and  young children.  Apart from the  platform that is stil  under  development,  Neema  organizes 
seminars for  mothers,  housemaids and caregivers  on  maternal and children  optimum  nutrition care and 
practices. 
The future passes by finalizing the platform, launching it to the market, in order to make it available 
for malnourished populations. 
  
  Tip sent example 
Pictures	12	–	Afya	Slices,	by	Neema	Shosho	
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Exhibit	13	- Raghuraj	Raju	(B3)	
Raghuraj  Raju is an entrepreneur from India,  born in  1982. In  2013,  he  was  diagnosed  with 
hypoglycaemia, and started to  perceive that chronic  healthcare conditions in  his country  were  not fuly 
monitored  by the responsible  doctors (India  has about  70 milion  patients suffering from chronic  health 
disorders). 
A year later he decided to create HealthPlix, a mobile app that connects patients to their responsible 
doctors in real-time  messaging.  Also, it enables  patients to record their  blood sugar,  meals, activity, and 
insulin intake. Doctors can charge patients through the app, by paying a one-time fee based on how long 
and how much they wil use the service. This solution also functions via SMS, however Raghuraj thinks 
that there is a lack of engagement in this way of approach. 
Currently the  mobile app  has in  diabetes and coronary  heart  diseases the  majority  of its  users.  This 
patient considers that feedback received and quickness to adjust to the market are the fundamental factors 
to success. “The need to have a good view of what is needed and the formation of an agile team” were also 
seen as equaly important. 
From the initial prototype, the patient already added to the app the possibility to integrate a patient’s 
medical  history (including the  medicine a person is taking) and some analytics to the  doctors (regarding 
treatments and their main failures) and provides them clinical insights, facilitating the doctor’s work, one 
type  of  users.  To the  other type, the  patients,  Raghuraj created a  more  user-friendly solution, thus 
increasing engagement. 
He  plans to target  more  doctors and  physicians treating chronic  problems, and expand into  other 
specialities such as  nephrologists,  dermatologists  or  paediatrics.  Additionaly,  he  wants to innovate and 
adopt artificial inteligence, creating an automatic response to users that want a doctor. 
  
Pictures	13	–	HealthPlix,	by	Raghuraj	Raju	
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Exhibit	14	- Fawad	Bhatti	(B4)	
Fawad  Bhati  was  born in  1994, in  Pakistan.  As an electrical engineering student,  he  developed 
Trequant while studying in the University, along with Usman Shabbir, who decided to leave the project. 
Although  Fawad’s  grandfather  was  diagnosed  with  Parkinson’s  disease,  his  doctor and family  were 
not  100% convinced  of that. It  was hard for  him to explain to the  doctor  his conditions,  vibrations and 
movements.  So,  Fawad  wanted to solve  his  grandfather’s  health  disorder  by  monitoring it (the  different 
food he ate, or the different activities performed during the days that were affecting his tremors), enabling 
his grandfather’s doctor to have access to how the he was feeling throughout the day, and not just at the 
moment he was visiting the hospital. 
Trequant is a mobile and desktop app that aims to track and analyse tremor paterns. Designed to help 
doctors to  understand  patient’s tremors  by analysing its  daily activities that affect the tremors, 
communicating this crucial information through a wearable device. It also, helps patients by offering some 
insights on the health disorder, providing tips on health habits, or activities to reduce the tremors, and they 
get  notifications  when it is time to take the  prescribed  medications.  There is also the community aspect, 
where patients can share their problems or solutions to other people with the same health problem. It also 
includes the  option to share the tremor intensities and colaborate in friendly chalenges that  motivates 
patients to perform daily exercises, beneficial to a tremor patient. 
The project had to end, due to a lack of financing, firstly because not many Pakistani investors would 
be wiling to invest on healthcare problems, so the caregiver adopted a crowdfunding way in order to have 
funds for market research and introducing the product to the market. 
  
  
Pictures	14	–	Trequant,	by	Fawad	Bhatti	
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Exhibit	15	- Mick	Ebeling	(B5)	
Mick Ebeling is the founder of Not Impossible, a company dedicated to "technology for the sake of 
humanity". Currently with 46 years of age, this American is a film, television and commercial executive 
producer, author, entrepreneur and philanthropist. 
After reading a Time Magazine article about a boy caled Daniel Omar, a 15 year-old Sudanese who 
lost both his hands after his vilage had been bombed, he decided to assemble a team and, in 2013, ilegaly 
traveled towards Nuba Mountains (Sudan), a commonly know active war zone, to provide him a prosthetic 
arm and to teach the community to create low cost prosthetic limbs. 
Daniel lost both arms while protecting himself from an aerial atack (by wrapping his arms around a 
tree,  which enabled  him to  protect  his  body  but  not  his arms).  After this,  Daniel  wished  he  had  died. 
Nowadays he is a double amputee, therefore he relied enormously on a caregiver, a 9 year-old child named 
Shaki, which had to feed him and bathe him, amongst other things. 
The  prosthetics arms cost  $100 to  produce and can  be  printed in about  6  hours.  Daniel cannot 
precisely control the fingers  or lift  heavy  objects, as the  printed arm is  not so sophisticated as high-end 
ones, but now he can do basic tasks like eat without the help of others. 
After these results, Mick has established a 3D printing lab nearby a Sudanese hospital. On the other 
side, Daniel is now living in Kenya, after the team rescued him out of a South Sudan refugee camp, where 
he was living. 
  
  
Pictures	15	–	3D	printing	arm,	by	Mick	Ebeling	
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Exhibit	16	- Indicators	Definition	
GNI	pc:	 sum	 of	 value	 added	 by	resident	 producers,	 plus	 product	 taxes	minus	 subsidies	
(not	included	the	output	valuation,	nor	net	receipts	of	primary	income,	compensation	of	
employees	and	property	income	from	abroad),	divided	by	the	midyear	population.	We	
choose	the	World	Bank’s	Atlas	Methodv	of	Conversion,	to	smooth	fluctuations	in	prices	
and	exchange	rates.	Data	referent	to	2015,	accordingly	with	World	Bank.	
Population:	number	of	residents	in	a	country,	regardless	their	legal	status	or	citizenship.	
This	data	is	referent	to	2015,	midyear	estimate,	and	accordingly	with	World	Bank.	
Education	level:	average	mean	of	school	years	(in	adults)	and	expected	school	years	(in	
children),	 both	 expressed	 as	 an	 index	 obtained	 by	 scaling	 with	 the	 corresponding	
maxima.	Data	referent	to	2013,	accordingly	with	the	UN.	
EL=	!"#$	&"#'(	)*	(+,))-.$/	.$0"1∗"13"+4"0	&"#'(	)*	(+,))-.$/	.$0"15!.$.!6!	-"7"-	7"'.*"0!#1.!6!	-"7"-	7"'.*."05!.$.!6!	-"7"-	7"'.*."0 	
Mortality	 rate,	 under-5:	 probability	 per	 1,000	 births	 a	 newborn	 baby	 wil	 die	 before	
reaching	 age	 5,	 if	 subjected	 to	 age-specific	 mortality	 rates	 of	 the	 specified	 year.	 Data	
referent	to	2015,	accordingly	with	World	Bank.	
Life	 expectancy	 at	 birth:	 number	 of	 years	 a	 newborn	 infant	 would	 live	 if	 prevailing	
patterns	 of	 mortality	 at	 the	 time	 of	 its	 birth	 were	 to	 stay	 the	 same	 throughout	 its	 life.	
Data	referent	to	2014,	accordingly	with	World	Bank.	
Multidimensional	poverty:	 percentage	 of	 multidimensionaly	poor	 population,	 adjusted	
by	intensity	of	deprivations	in	terms	of	education,	health	and	living	standards.	Refers	to	
diferent	years	due	to	inconsistencies	for	some	nations,	accordingly	with	the	UN.	
Population	 undernourished:	Proportion	 of	 population	 below	 the	 minimum	 level	 of	
dietary	energy	consumption.	This	data	is	referent	to	2015	and	accordingly	with	the	UN.	
Human	Development	Index:	geometric	mean	of	normalized	indices	for	three	dimensions:	
long	 and	 healthy	 life,	 knowledge	 and	 decent	 standard	 of	 living.	Data	referent	 to	 2015,	
accordingly	with	the	UN.	
Mobile	phone	 subscriptions:	Number	 of	 subscriptions	 for	 mobile	 phone	 services	
(including	 the	 number	 of	 post-paid	 subscriptions	 and	 the	 number	 of	 active	 prepaid	
accounts).	Data	referent	 to	 2015,	expressed	 per	 100	 people,	accordingly	 with	 World	
Bank.	
Internet	 users:	Population	 with	 access	 to	 worldwide	 network.	Data	referent	 to	 2015,	
expressed	 per	 100	 people,	 accordingly	 with	 World	 Bank.
                        
v	http://bit.ly/20hZJ7K	
	Exhibit	17	- Analysed	Countries	
 Economic Social 
Country GNI pcvi 
Population 
(‘000)vii 
Education 
levelviii 
Mortality 
under-5ix 
Life expectancy 
at birthx 
Multidimensio
nal povertyxi 
Population 
undernourishedxii 
HDIxiii 
Mobile 
usersxiv 
Internet 
usersxv 
Africa 
Benin $840.0  10879,83 0.414 100 60 0.343 (2012)  7.5% 0.485 86 7 
Burkina Faso  $640.0  18105,57 0.250 89 59  0.508 (2010)  20.7% 0.402 81 11 
Burundi $260.0  11178,92 0.370 82 57 0.442 (2010)  n.a. 0.404 46 5 
Cameroon  $1 320.0  23344,18 0.486 88 55  0.260 (2011)  9.9% 0.518 72 21 
Central African Republic $330.0  4900,27 0.318 130 51 0.424 (2010)  47.7% 0.352 26 5 
Chad $880.0  14037,47 0.256 139 52 0.545 (2010)  34.4% 0.396 40 3 
Comoros $780.0  788,47 0.450 74 64 0.165 (2012)  n.a. 0.497 55 7 
Congo $2 540.0  4620,33 0.511 45 63 0.192 (2012)  30.5% 0.592 112 8 
Côte D'Ivoire $1 420.0  22701,56 0.389 93 52 0.307 (2012)  13.3% 0.474 119 21 
DRCxvi  $410.0  77266,81 0.372 98 59  0.369 (2014)  n.s.xvii 0.435 53 4 
Djibouti n.a.xviii 887,86 0.306 65 62 0.128 (2006)  15.9% 0.473 35 12 
Eritrea n.a. n.a. 0.228 47 64 n.a.  n.a. 0.420 7 1 
Ethiopia  $590.0  99390,75 0.317 59 64  0.537 (2011)  32.0% 0.448 43 12 
The Gambia n.a.  1990,92 0.346 69 60 0.289 (2013)  5.3% 0.452 138 17 
Ghana  $1 480.0  27409,89 0.553 62 61  0.144 (2011)  5.0% 0.579 130 24 
Guinea  $470.0  12608,59 0.294 94 59  0.425 (2012)  16.4% 0.414 87 5 
Guinea Bissau $590.0  1844,33 0.325 93 55 0.495 (2006)  20.7% 0.424 69 4 
Kenya  $1 340.0  46050,3 0.515 49 62  0.226 (2009)  21.2% 0.555 81 46 
Lesotho $1 280.0  2135,02 0.504 90 50 0.227 (2009)  11.2% 0.497 101 16 
Liberia $380.0  4503,44 0.367 70 61 0.356 (2013)  31.9% 0.427 81 6 
Madagascar $420.0  24235,39 0.458 50 65 0.420 (2009) 33.0% 0.512 44 4 
Malawi  $340.0  17215,23 0.440 64 63  0.332 (2010)  20.7% 0.476 35 9 
                                                vi	http://bit.ly/2rTj9qp	vii	http://bit.ly/2rTKeKg	viii	http://bit.ly/1pHdX3Q	ix	http://bit.ly/2qfrLKZ	x	http://bit.ly/2qj9A31	xi	http://bit.ly/1kYwvXA	xii	http://bit.ly/2rTvtqV	xiii	Human	Development	Index	(http://bit.ly/2niumB7)	xiv	http://bit.ly/2qfrwQg	xv	http://bit.ly/2qfmJhm	xvi	Democratic	Republic	of	Congo	xvii	not	significant	xviii	not	available	
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Mali  $760.0  17599,69 0.305 115 58  0.456 (2013)  5.0% 0.442 140 10 
Mauritania n.a. 4067,56 0.352 85 63 0.291 (2011)  5.6% 0.513 89 15 
Mozambique  $590.0  27977,86 0.372 79 55  0.390 (2011)  25.3% 0.418 74 9 
Niger $390.0  19899,12 0.198 96 62 0.584 (2012)  9.5% 0.353 46 2 
Nigeria  $2 820.0  182201,96 0.425 109 53  0.279 (2013)  7.0% 0.527 82 47 
Rwanda  $700.0  11609,67 0.478 42 64  0.352 (2010)  31.6% 0.498 70 18 
Senegal  $980.0  15129,27 0.368 47 66  0.278 (2014)  24.6% 0.494 100 22 
Sierra Leone $620.0  6453,18 0.305 120 51 0.411 (2013) 22.3% 0.420 90 3 
Somalia n.a.  10787,1 n.a. 137 55 0.500 (2006) n.s. n.a. 52 18 
South Sudan  $790.0  12339,81 n.a. 93 56  0.551 (2010)  n.s. 0.418 24 27 
Sudan  $1 920.0  40234,88 0.306 70 63  0.290 (2010)  n.s. 0.490 71 2 
Swaziland $3 280.0  1286,97 0.551 61 49 0.113 (2010)  26.8% 0.541 73 30 
Tanzania  $920.0  53470,42 0.426 49 65  0.335 (2010)  32.1% 0.531 76 5 
Togo  $540.0  7304,58 0.514 78 60  0.242 (2014)  11.4% 0.487 65 7 
Uganda  $700.0  39032,38 0.479 55 58  0.359 (2011)  25.5% 0.493 50 19 
Zambia  $1 490.0  16211,77 0.591 64 60  0.264 (2014)  47.8% 0.579 74 21 
Zimbabwe  $860.0  15602,75 0.500 71 57  0.128 (2014)  33.4% 0.516 85 16 
Asia 
Afghanistan  $610.0  32526,56 0.365 91 60  0.293 (2011)  5.0% 0.479 62 8 
Bangladesh  $1 190.0  160995,64 0.447 38 72  0.237 (2011)  16.4% 0.579 83 14 
India  $1 600.0  1311050,53 0.473 48 68  0.282 (2006)  15.2% 0.624 79 26 
Indonesia  $3 440.0  257563,82 0.603 27 69  0.024 (2012)  7.6% 0.889 132 22 
Nepal  $730.0  28513,7 0.452 36 70  0.197 (2011)  7.8% 0.558 97 18 
Pakistan  $1 440.0  188924,87 0.372 81 66  0.237 (2013)  22.0% 0.550 67 18 
Papua New Guinea n.a. 7619,32 0.376 57 63 n.a.  n.a.  0.516 47 8 
Philippines  $3 550.0  100699,4 0.610 28 68  0.033 (2013)  13.5% 0.682 118 41 
Solomon Islands $1 920.0  583,59 0.405 28 68 n.a.  11.3% 0.515 73 10 
Syrian Arab Republic n.a.  18502,41 0.553 13 70 0.028 (2009) n.a. 0.536 64 30 
Vietnam  $1 990.0  91703,8 0.513 22 76  0.026 (2011)  11.0% 0.683 131 53 
Yemen $1 140.0  26832,22 0.339 42 64 0.200 (2013) 26.1% 0.482 68 25 
South America 
Haiti  $810.0  10711,07 0.374 69 63  0.242 (2012)  53.4% 0.493 70 12 
Honduras  $2 280.0  8075,06 0.505 20 73  0.098 (2012)  12.2% 0.625 96 20 
Nicaragua  $1 940.0  6082,03 0.484 22 75  0.088 (2011)  16.6% 0.645 116 20 
Table	9	-	Analysed	Countries	
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Exhibit	18	- User	Innovators	Found	
 
Country of 
Innovation Country of birth Age Gender Education Occupation Condition Type Solution 
Africa 
Burkina Faso Burundi Born in 1978 Male University Degree Entrepreneur Malaria Patient Faso Soap 
Cameroon Cameroon Born in 1992 Male University Degree Engineer Maternal-death Collaborator Gifted-Mom 
Cameroon Cameroon Born in 1988 Male University Degree Engineer Heart diseases Caregiver CardioPad 
Chad Chad Born in 1984 Male University Degree Doctor Schistosomiasis Collaborator DAWA Mobile Health 
DRC DRC Born in 1980 Male Primary School Entrepreneur Polio Patient Three-wheeled wheelchair 
DRC DRC n.a.xix Male University Degree Entrepreneur Malaria Collaborator PaluCheck 
Ghana Ghana Born in 1984 Male University Degree Entrepreneur Cancer Caregiver MOJA 
Ghana Ghana n.a. Female University Degree Nurse Autism Caregiver AACT 
Kenya UK Born in 1980 Male University Degree Ophthalmologist Vision problems Collaborator PEEK Vision 
Mali Mali n.a. Male University Degree Doctor Medical personnel shortage Collaborator Bogou 
Nigeria Nigeria Born in 1966 Male University Degree Biotechnologist Malaria Patient Urine Malaria Test 
Rwanda Rwanda Born in 1994 Male High School Entrepreneur Physical disability Caregiver Low-cost hand bike 
Sudan USA Born in 1970 Male University Degree Entrepreneur Physical disability Collaborator 3D Prosthetic Arm 
Sudan Sudan Born in 1999 Male High School Student Physical disability Collaborator Robotic Arm 
Senegal 
Senegal Born in 1993 Male University Degree Entrepreneur Blood transfusion Patient HOPE: Mon Sang Pour 
Sauver Des Vies Cameroon Born in 1994 Female University Degree Entrepreneur Leukaemia Caregiver 
Uganda Uganda Born in 1991 Female University Degree Engineer Pneumonia Caregiver Mama-Ope 
Uganda Uganda Born in 1993 Male University Degree Engineer Malaria Patient Matibabu 
Tanzania Tanzania Born in 1986 Female University Degree Nutritionist Malnutrition Caregiver Afya Slices 
Tanzania Tanzania Born in 1977 Male University Degree Engineer Water related diseases Patient Nanofilter® 
Asia 
Afghanistan Afghanistan n.a. Male University Degree Doctor Physical disability Caregiver Sadat Fixation Device 
India India Born in 1998 Female High School Student Water related diseases Collaborator Water purification system 
India India Born in 1984 Male University Degree Doctor Throat cancer Caregiver Entraview 
India India Born in 1957 Male University Degree Surgeon Impossibility to speak Collaborator Vocalizer 
India India Born in 1999 Male High School Student Physical disability Caregiver EEG Prosthetic arm 
India India Born in 2000 Male High School Student Lack of access to vaccination Patient VAXXWAGON 
India India Born in 1985 Female University Degree Designer Deaf at birth Caregiver Sohum 
India India Born in 1982 Male University Degree Engineer Diabetes Patient HealthPlix 
India India Born in 1982 Male University Degree Pharmaceutic Diabetes Caregiver Diabeto 
Indonesia Indonesia Born in 1985 Male University Degree Doctor Lack of access to healthcare Collaborator ProSehat 
Indonesia Singapore Born in 1993 Male University Degree Doctor Lack of access to healthcare Collaborator RingMD 
Indonesia Indonesia Born in 1984 Male Secondary School Welder Physical disability Patient EEG Prosthetic arm 
Pakistan Pakistan Born in 1994 Male University Degree Engineer Parkinson Caregiver Trequant 
                                                xix	not	available	
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Philippines Philippines Born in 1969 Male University Degree Entrepreneur Dengue Patient Blood Donors Network 
Syrian Arab Republic Syrian Arab Republic n.a. Male High School n.a. Physical disability Patient Electric bycicle 
South America 
Haiti USA 
Born in 1977 Male University Degree Pastor 
Diarrhoea Collaborator DriButts 
Born in 1977 Female University Degree Nurse 
Honduras Honduras Born in 1995 Male High School Student Physical disability Caregiver EyeBoard 
Table	10	-	User	Innovators	found	
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Exhibit	19	- Sample	
 
Country of innovation Solution Relation with the need Source of data Date Duration (min) 
Burkina Faso Malaria prevention soap Patient Interview 29.03.2017 39 
Chad Health monitoring platform Collaborator Interview 13.04.2017 60 
Ghana Blood donation platform Caregiver Interview 23.03.2017 38 
Nigeria Urine Malaria Test Patient Survey 27.05.2017 n.a.xx 
Rwanda Low-cost hand bike Caregiver Interview 23.03.2017 74 
Sudan 3D Printing Arm Collaborator Survey 30.05.2017 n.a. 
Senegal Blood donation platform Patient/Caregiver Interview 28.03.2017 55 
Uganda Malaria testing device Patient Interview 23.03.2017 42 
Uganda Pneumonia detection shirt Caregiver Survey 04.05.2017 n.a. 
Tanzania Malnutrition monitoring platform Caregiver Survey 03.04.2017 n.a. 
Tanzania Low cost water filtration system Patient/Caregiver Interview 12.03.2017 41 
India 
Chronic diseases monitoring 
platform 
Patient Interview 27.03.2017 72 
Pakistan Tremors monitoring platform Caregiver Interview 27.03.2017 41 
Philippines Blood donation platform Patient Interview 20.03.2017 64 
Haiti Reusable diapers Collaborator Interview 12.04.2017 65 
Table	11	-	Data	Gathering
                                                xx	non-applicable	
	Exhibit	20	- Questionnaire	
Dear creator, 
We would like to invite you to fil out this questionnaire, aiming to obtain findings for my thesis, 
which focuses  on solutions  developed  by  patients, and/or their caregivers living in  developing 
countries to overcome a problem or a need imposed by a health condition or disorder. 
I am curently working in colaboration with a research project caled Patient Innovation, an online 
and free-access repository  of  open  knowledge containing  healthcare solutions  where  patients and 
caregivers from al around the world share their knowledge and solutions with others with the same 
need (htps:/patient-innovation.com/).  The  biggest advantage  of this  platform is its  network efect: 
the more patients or caregivers that share their solutions, more information wil be available to those 
who are looking for answers for their  problems and the  higher the  potential  value  of each solution 
proposed. We invite you to share your solution in our community! 
 We are trying to figure it  out the environment in  which the innovators live, their limitations in 
regards to healthcare support. Therefore, if your want to remain anonymous please put a cross (X) on 
the folowing  question.  Your information is just for research  purposes  only,  not for commercial 
means.  
Do	you	want	to	remain	anonymous?	
Yes	 	
No	 	
	
 
 
 
(I) Information about health disorder 
1) 
Which was the diagnosis for the patient’s health condition? 
Answer: 
 
2) 
For how long has the patient lived (or stil lives) with the health disorder? When was it diagnosed? 
Answer: 
 
3) 
Briefly describe the major limitations on daily activities caused by the health disorder. 
Answer: 
 
4) 
Exactly which problem did you want to solve? How did you solve it? 
Answer: 
 
(II) Initial knowledge on the health disorder 
Please put a cross (✗) on the answer that satisfies you the most. 
5) 
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  What is your opinion on the information given by your doctor? 
- It is clear and provided me valuable information  
- Provided me some basic insights but it was not enough  
- The responsible doctor did not explain the condition in a proper manner  
- It is not sufficient for a person with my health disorder  
- Other: 
 
6) 
Did you seek for more information about the health disorder? 
- No more than what the responsible doctor told  
- Asked a second opinion, from another doctor  
- Talked with patients that have a similar health disorder  
- Searched. How many hours?  
 Less than 25 hours per week  
 Between 25 and 50 hours per week  
 More than 50 hours per week  
- Other: 
 
If you searched for more information, please answer the following questions. Otherwise you can 
move onto the next section. 
7) 
How did you perform your search about the health disorder? 
- Searched more information about the health disorder and its symptoms  
- Searched for solutions created to overcome the limitations to similar specific problems  
- Other 
 
8) 
Where did you search for that additional information? 
- Online (via social networks, websites, blogs)  
- Offline (via newspapers, medical journals, articles)  
- A company provided more information about this specific health disorder  
- Contacted the respective patient association  
- Other: 
 
(III) Solution 
9) 
At the beginning what was the major problem that you wanted to solve? 
Answer: 
 
10) 
Can you briefly describe your solution? (How was the process? Any differences from the initial prototype?) 
Answer: 
 
Please put a cross (✗) on the answer that satisfies you the most. 
11)  
Why did you create this solution? 
- Lack of good quality infrastructures  
- Lack of competent medical personnel  
- Lack of good accesses to medical infrastructures  
- Lack of information provided  
- Other: 
 
12) 
What is your opinion about the current solutions on the market? 
- There was no alternative on the market  
- The current products did not satisfy my needs  
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- The current alternatives on the market are too expensive  
- Other: 
 
On a scale from 1 to 7 (being 1, irrelevant and 7, fundamental), please classify the 
following aspects: 
13) 
How relevant were the following conditions for your creation? 1 2 3 4 5 6 7 
- Access to internet connection        
- Access to mobile connection        
- Access to medical facilities and personnel        
- Access to pharmaceutical drugs        
- Household access to potable water        
- Visits from medical personnel to faraway villages        
- Lack of public healthcare policies to prevent and monitor diseases        
- Role of community (to give the idea, or help him to create)        
- Access to education        
- Access to facilities to develop the solution        
- Other: 
 
 
(IV) Diffusion 
Please put a cross (✗) on the answer that satisfies you the most. 
14)  
Did you tell anyone about the solution that you created? Who? 
- Relatives  
- Friends  
- Patients with a similar health condition  
- Responsible doctor  
- Other: 
 
15) 
How did you do it? 
- Talked with friends and/or relatives, other patients, responsible doctor  
- Shared via online channels (social networks, websites, blogs)   
- Shared via offline channels (newspapers, medical journals, articles)  
- Other: 
 
16)  
What was the feedback received? 
- All the people found it useful  
- Most of the people found it useful  
- Some people found useful and provided me feedback  
- Some people found useful but did not provided feedback  
- Most of the people did not find it useful  
- No one found it useful  
- Other: 
 
17) 
Besides yourself, this solution is valuable to: 
- No one  
- Few others  
- Many others  
- Nearly anyone  
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18) 
Did you protect your Intellectual Property rights somehow? 
- Yes  
- No  
 
19) 
If you have answered question 18 with “Yes”: 
Why did you do it? 
- Perceive a good commercialization opportunity  
- Other 
 
20) 
If you have answered question 18 with “No”: 
Why did you choose not to protect? 
- It is difficult to present the product’s novelty  
- I would like to share it openly  
- Did not worth the cost  
- Could reduce the interest from potential adopters  
- Other: 
 
21) 
What are the next steps for the solution? 
Answer: 
 
22) 
Do you think this solution could be used in developed countries (like, Europe and/or in the United States of 
America)? Why? 
Answer: 
 
 
(V) Personal information 
23) 
Gender 
Male  
Female  
Age  
 
24) 
What is your country of birth? 
Answer: 
 
25) 
What is your country of residence? 
Answer: 
 
Please put a cross (✗) on the answer that satisfies you the most. 
26) 
What is your level of education? 
- Primary School  
- Secondary School  
- High School  
- University Degree  
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27) 
What was your employment status during the development of your solution? 
- Student  
- Employed  
- Unemployed  
 
28) 
What is your relation with the need? 
- Patient  
- Friend or relative  
- Met the patient/community and wanted to solve its problem  
 
29) 
How did you come up with this solution?  
- Did you see a commercial on TV about a similar one on another country? Which one?  
- Talked with a university friend? From which country?  
- A relative mentioned something similar in another region?  
- Other: 
 
 
Your help wil be an asset to my Thesis and we want to highlight that without you it would not be 
possible for us! 
 
Thank you very much for your cooperation! 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	 	 76	
Exhibit	21	- Interview	Script	
I. Information	about	health	disorder	a) Which	was	the	diagnosis	for	the	patient’s	health	condition?	b) For	how	long	has	the	patient	lived	(or	still	lives)	with	the	health	disorder?	When	was	it	diagnosed?	c) Briefly	 describe	 the	 major	 limitations	 on	 daily	 activities	 caused	 by	 the	 health	disorder.	d) Exactly	which	problem	did	you	want	to	solve?	How	did	you	solve	it?	
II. Initial	knowledge	on	the	health	disorder	a) What	is	your	opinion	on	the	information	given	by	the	doctor	on	the	health	disorder?	b) Did	you	seek	for	more	information	about	the	health	disorder?	c) How	did	you	perform	your	search	about	the	health	disorder?	d) Where	did	you	search	for	that	additional	information?	
III. Solution	a) At	the	beginning	what	was	the	major	problem	that	you	wanted	to	solve?	b) Can	you	briefly	describe	your	solution?	(How	was	the	process?	Any	differences	from	the	initial	prototype?)	c) Why	did	you	create	this	solution?	d) What	is	your	opinion	about	the	current	solutions	on	the	market?	e) Could	you	characterize	the	following	conditions	on	your	country?	And	on	a	scale	from	1	to	7	(being	1,	irrelevant	and	7,	fundamental),	please	classify	the	following	aspects:	i. Access	to	internet	connection	ii. Access	to	mobile	connection	iii. Access	to	medical	facilities	and	personnel	iv. Access	to	pharmaceutical	drugs	v. Household	access	to	potable	water	vi. Visits	from	medical	personnel	to	faraway	villages	vii. Lack	of	public	healthcare	policies	to	prevent	and	monitor	diseases	viii. Role	of	community	to	give	you	the	idea	ix. Role	of	community	to	help	you	to	develop	the	solution	x. Access	to	education	xi. Access	to	facilities	to	develop	the	solution	
IV. Diffusion	a) Did	you	tell	anyone	about	the	solution	that	you	created?	Who?	b) How	did	you	do	it?	c) What	was	the	feedback	received?	d) Beside	yourself,	do	you	think	this	solution	is	valuable	to	anyone?	e) Did	you	protect	your	Intellectual	Property	rights	somehow?	
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f) Why	did	you	do	it?	(or	Why	did	you	choose	not	to	protect?)	g) What	are	the	next	steps	for	the	solution?	h) Do	you	think	this	solution	could	be	used	in	developed	countries?	Why?	
V. Personal	information	a) Gender	b) Age	c) What	is	your	country	of	birth?	d) What	is	your	country	of	residence?	e) What	is	your	level	of	education?	f) What	was	your	employment	status	during	the	development	of	your	solution?	g) What	is	your	relation	with	the	need?	h) How	did	you	come	up	with	this	solution?	
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Exhibit	22	- Evaluation	for	Reverse	Innovation	
 
Innovator Physician 1 Physician 2 Physician 3 
A1 
“Interesting, but the 
product needs to be tested 
in a correct manner.” 
“It might be interesting as a tactical 
method as it promotes a natural 
product developed to protect from 
malaria, this aspect is crucial for 
the developed countries as we travel 
more and more (…)” 
“Europe is a “malaria free” 
region, as well as USA, 
therefore I do not thing it is a 
useful solution for developed 
countries.” 
A2 “Useful in cases of outbreaks.” 
“We have many ways to test in a 
lab… Probably it is not of a big use 
in developed countries, unless costs 
are lower.” 
“Do not sound interesting for 
the reality of developed 
countries.” 
A3 
“The approach of taking 
advantage of ambassadors 
is interesting.” 
“Fortunately, they retrieve the direct 
constant contact. No interest for 
countries like Portugal.” 
“In developed countries there 
is already an integrated 
network of information and 
cooperation, regarding blood 
banks.” 
A4 “Existence of common databases.” 
“(…) only a few types of blood are 
scarce enough to cause death in a 
developed country, nevertheless this 
app would definitely improve 
donation by constant awareness.” 
“In developed countries there 
is already an integrated 
network of information and 
cooperation, regarding blood 
banks.” 
A5 
“Good for regions without 
doctors, not the case of 
the majority of developed 
countries.” 
“Interesting for educational 
purposes in developed countries or 
for a one to one use and contact 
with the medical doctor via 
telemedicine.” 
“Do not seems interesting for 
our reality.” 
A6 “Important if results are proven.” 
“(…) great for this or other diseases 
use. It could be interesting to 
commercialize in developed 
countries for detection and to sell as 
a travel kit.” 
“Amazing! Very interesting.” 
A7 
“Not health related, but 
interesting for countries 
like Portugal.” 
“It could be transferred if it is 
turned into individual portable 
devices…” 
“I do not think it would have 
applicability in developed 
countries.” 
A8 “Existence of common databases.” 
“I do not see a high benefit, maybe 
as a model to improve national 
networks.” 
“Do not seems interesting for 
our reality.” 
A9 “Not good for patients due to the risk of infections.” 
“(…) it would be interesting to a 
small portion of society.” 
“In developed countries there 
is already an integrated 
network of information and 
cooperation, regarding blood 
banks.” 
A10 “Interesting if cheaper and if data available.” 
“Astronomical potential to be used 
as screening in both developing and 
developed countries. Besides, it is 
not a blood-dependent operator, 
which is a benefit.” 
“Looks interesting, regarding 
the diagnosis times and the 
price as well. Could be 
adopted by developed 
countries.” 
 
B1 
“Interesting the affordable 
approach, but very 
primitive.” 
“Interesting as an “awareness 
marketing” tool.” 
“I do not think it would be 
applicable to developed 
countries because it does not 
fit the reality in which we 
live.” 
B2 “Could be useful for developed populations.” 
“It is a trend to focus on these 
subjects, probably as the awareness 
of the importance of good food 
“There is so much available 
information in developed 
countries, I do not know the 
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choices is higher in developed 
countries the app would have a 
higher impact. Devices access is 
higher in developed countries.” 
impact of this.” 
B3 
“We have something like 
this already in developed 
countries.” 
“It is similar to some new apps in 
the market. If well balanced and 
agreed between all the stakeholders 
with definite boundaries it would do 
good competition.” 
“Sounds interesting, but I am 
not sure about the openness 
of my colleagues regarding 
this business model.” 
B4 
“One unmet need, but 
needs to be clearly 
tested.” 
“Due to awareness and a better 
Maslow Pyramid position, I guess it 
would have a higher impact in 
developed countries than in a 
developing one.” 
“Interesting and applicable 
to developed countries.” 
B5 
“Affordable approach, 
interesting for people who 
cannot go to 
manufacturers.” 
“May be very interesting while 
children are growing and they need 
to change prosthetics very often 
(lower price, similar positive 
impact).” 
“Amazing!” 
Table	12	-	Evaluation	for	Reverse	Innovation	
 
Green Solutions potentially adoptable by developed countries 
Yellow Solutions can be adopted if user innovators apply changes 
Red 
Solutions do not have the potential to be adopted by developed 
countries 
 
